Systematic Review and Meta-Analysis

Investigation into the clinical performance of rectus sheath block in reducing postoperative pain following surgical intervention: A systematic review and meta-analysis of randomised controlled trials

Address for correspondence:

Prof. Thomas M. Hemmerling, Department of Anaesthesiology and Experimental Surgery, McGill University and Montreal General Hospital, 1650 Cedar Ave, T8-108, Montreal, Quebec H3G 1A4, Canada. E-mail: Thomas.Hemmerling@ mcgill.ca

> Submitted: 12-Nov-2023 Revised: 10-Jan-2024 Accepted: 11-Jan-2024 Published: 29-Jan-2024

Access this article online

Website: https://journals.lww. com/ijaweb

DOI: 10.4103/ija.ija_1099_23

Quick response code



Sean D. Jeffries^{1,2}, Robert Harutyunyan¹, Joshua Morse¹, Thomas M. Hemmerling^{1,2} ¹Department of Experimental Surgery, McGill University Health Center, Montréal, ²Department of Anaesthesia, McGill University, Montréal, Canada

ABSTRACT

Background and Aims: Rectus sheath block (RSB) is an effective postoperative pain control technique in abdominal surgical procedures. This systematic review evaluated the efficacy and outcome data of patients undergoing RSB compared to the standard of care in both laparoscopic and open surgical procedures. Methods: This systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (PROSPERO ID: CRD42022372596). The search was restricted to randomised controlled trials (RCTs) comparing RSB effectiveness on postoperative pain to any standard general anaesthesia technique (control). We systematically explored PubMed, Medline, Central, Scopus and Web of Science for RCTs from inception to September 2023. The primary outcome was the evaluation of pain scores at rest 0-2, 10-12 and 12-24 h postoperatively. The secondary outcome was the analysis of postoperative intravenous (IV) morphine equivalent consumption at 24-h. A risk-of-bias tool for randomised trials (ROB 2.0, Cochrane, Copenhagen, Denmark) assessment and Grades of Recommendation, Assessment, Development and Evaluation (GRADE, Cochrane, Copenhagen, Denmark) analysis was conducted to evaluate the quality of the RCTs. Results: Twenty RCTs involving 708 participants who received RSB intervention and 713 who received alternative analgesic care were included. RSB pain scores were significantly lower than control at 0-2 h (P < 0.001) and 10-12 h (P < 0.001) postoperatively. No significant effect was observed at 24 h (P = 0.11). RSB performance compared to control in 24-h IV morphine equivalency in milligrams was significantly lower (P < 0.001). Conclusion: RSB implementation was associated with reduced postoperative pain scores and decreased opioid consumption in IV morphine equivalency up to 24 h following surgical intervention.

Key words: Abdominal surgery, postoperative pain, rectus sheath block, regional anaesthesia, systematic review

INTRODUCTION

The rectus sheath block (RSB) was initially described and utilised in 1899 to relax the abdominal muscles during laparotomy before the adjunct of neuromuscular blocks.^[1] It involves the administration of local anaesthetic through the rectus abdominis muscle onto the posterior wall of the rectus sheath, effectively blocking the seventh to twelfth terminal branches of the intercostal thoracic nerves.^[2] More often, the modern version of the technique utilises ultrasound-guided vision to insert needles better and accurately deposit the anaesthetic – increasing the overall efficacy of

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: WKHLRPMedknow_reprints@wolterskluwer.com

How to cite this article: Jeffries SD, Harutyunyan R, Morse J, Hemmerling TM. Investigation into the clinical performance of rectus sheath block in reducing postoperative pain following surgical intervention: A systematic review and meta-analysis of randomised controlled trials. Indian J Anaesth 2024;68:142-52.

injections.^[3,4] Injection can be done unilaterally or bilaterally into the rectus muscle or through surgical and laparoscopic interventions.^[3,5]

Previous reports have highlighted the RSB's potential analgesic effectiveness in managing postoperative pain but have been limited in their search and scope. They appear to present a degree of uncertainty in their findings.^[6] For example, a recent 2020 review on the analgesic efficacy of the RSB investigated nine studies using postoperative pain scores as a practical endpoint but was limited in its search criteria by focusing solely on adult laparoscopic procedures.^[7] In 2016, a combined analysis was performed exploring the efficacy of RSB and transverse abdominal plane blocks in children; however, despite including both laparoscopic and open abdominal surgeries, only five trials were selected for the RSB group.^[8] In a more recent 2022 article, Zhen et al.^[9] also explored the efficacy of the RSB in paediatric umbilical hernia repairs; yet again, due to their constraints, they included only four trials in their review. Since the RSB is currently recognised as a viable choice for pain relief in various abdominal procedures, and more potentially diverse randomised controlled trials (RCTs) investigating its broader efficacy have likely been published, an updated review of the literature is warranted.

In this systematic review and meta-analysis, we attempted to address the degree of uncertainty in the literature by compiling all available studies on the analgesic efficacy of the RSB following abdominal surgery. The study's objective was to assess the efficacy of the RSB in reducing postoperative pain following abdominal surgery, as compared to established anaesthetic techniques. We hypothesise that the RSB will be seen as an effective anaesthetic method for abdominal operations, outperforming conventional general anaesthesia approaches in both the reduction of postoperative pain and 24-h intravenous (IV) morphine equivalent consumption.

METHODS

Study protocol

This systematic review and subsequent meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocol (PRISMA-P).^[10] The study protocol was registered prospectively on the International Prospective Register of Systematic Reviews (PROSPERO ID: CRD42022372596).

Inclusion and exclusion criteria

The studies included in this review were selected based on the PICOS (Population, Intervention, Comparator, Outcome and Study) framework. The population was hospitalised participants of any age who underwent an abdominal surgical procedure in which the intervention was the use of RSB. The comparator for this study was any reasonable alternative control such as placebo, wound infiltration, port-site infiltration, local anaesthetic, continuous drip infusion and epidural anaesthesia. The primary outcome was the efficacy of RSB at various reasonably spaced time points throughout postoperative recovery. The secondary outcome was 24-h IV morphine equivalent consumption. Reviews, conference abstracts, letters to the editor, systematic reviews, meta-analyses, case reports, combined blocks and non-comparative and retrospective studies were excluded.

Exclusion criteria were met if a study was irrelevant to the RSB technique, was a technical description/proceeding, utilised combined blocks, was non-randomised, did not include human models or if a study was a case report and case series. Among the publications identified, we excluded studies that did not report postoperative pain scores during at least one of the time points necessary to analyse the primary outcome.

Search strategy

We systematically explored and retrieved studies for analysis from the US National Library of Medicine database (PUBMED), Medline (Ovid), Cochrane Central Register of Controlled Clinical Studies (CENTRAL), the Elsevier Scopus Database (SCOPUS) and the Web of Science online Database (Web of Science). An additional manual search strategy was also implemented to identify studies not retrieved through electronic search, as recommended by Chapman et al.^[11] 2010. The database and manual search were conducted by reviewer [SDJ]. Selected papers were all RCTs published from inception to 1 September, 2023. Eligibility was limited to include English language, and human participant studies only. Identification of relevant studies through title and abstract screening was subsequently performed by at least two independent reviewers [SD] and RH] for identification of potentially eligible studies. A third reviewer [TH] was available upon request to finalise any conflicts in the study and data selection.

The basic search strategy (in titles, abstracts and/or all fields) was as follows. Search query: ALL (rectus

sheath block OR abdominal field block OR anaesthesia OR analgesia OR block OR inject OR infusion) AND ALL (randomised control trial OR controlled OR clinical trial OR randomised) – Articles type: RCT Trials only - Publication year: Inception–Sept 2023 [SDC Table 1].

Data extraction and synthesis

studies were collected All first into the Rayyan intelligent, systematic review tool for deduplication, abstract screening and initial study selection.^[12] Deduplication occurred electronically, while independent reviewers manually performed initial abstract screening and study selection [SJ, RH] using predefined criteria in the attached protocol. A data collection sheet was then created with the following items extracted: authors, year of publication, surgical procedure, RSB technique, RSB timing, RSB drug, control intervention and postoperative analgesia regimen.

Following article screening, independent reviews performed a full-text review and assessment for inclusion again [SDJ, RH]. If necessary, a third blinded reviewer resolved conflicts involving inclusion between reviewers [TH]. Selected articles underwent Grades of Recommendation, the Assessment, Development and Evaluation (GRADE) guidelines to evaluate the methodological quality of evidence for pooled outcomes with three or more studies.^[13] These guidelines classify the evidence for pooled outcomes using predefined criteria, such as study quality, consistency, directness, precision and publication bias.^[13] A final sample of 20 studies were selected for inclusion. The risk of bias in individual studies selected was further assessed using the revised Cochrane risk-of-bias tool for randomised trials (RoB 2.0, Cochrane, Copenhagen, Denmark).^[14] When one study included more than two arms, data was extracted from both experimental groups only if separate participants were used. Each comparison was treated as an independent study in these cases, maintaining the assumption of independence.^[15]

Outcomes

The primary outcome was reported as the difference in pain scores at 0-2 h, 10-12 h, and 12-24 h postoperatively, measured through visual or numerical pain rating scales (0-10 scale, with 0 indicating no pain and 10 representing the worst pain imaginable). Any scale that did not fall under these criteria was appropriately converted for further analysis. The secondary outcome was measured as 24-h IV morphine equivalent consumption. Any participants who received opiates other than IV morphine had their treatment converted to IV morphine equivalents.^[16,17]

Statistical analysis

Analyses were performed using the Review Manager statistical software, version (Cochrane, 5.4.1Copenhagen, Denmark). In scenarios where continuous variables were displayed as medians, ranges or interquartile ranges, the authors calculated the mean pain score and standard deviation using the methodology described in Luo et al.^[18] and Wan et al.^[19] If exact data was not reported, authors were contacted; if authors did not reply, the RCT was removed from inclusion in this study. If only graphical representations of data were available, means and standard deviations would be extracted using the pixel-based computer software 'WebPlotDigitizer', an HTML5-based online tool that enables the extraction of numerical data from plot images.^[20]

Continuous outcomes were pooled and assessed via standardised mean differences (SMD) in a random-effects model with a 95% confidence interval (CI). High heterogeneity was expected due to the diversity of RSB applications and methodologies in the various abdominal surgical procedures.^[21] A Dersomonian and Laird, random-effects model, was thus chosen to mitigate potential heterogeneity, as the effects estimated from the different studies likely still follow a particular distribution despite not having identical parameters.^[22,23] A subgroup analysis was conducted to explore potential sources of heterogeneity further and evaluate the efficacy of RSB in laparoscopic and open surgery separately. The I² statistic was used to describe the exact percentage of the variability in effect estimates due to heterogeneity, graded as low: <30%, moderate: 30%–60%, substantial: 60%-75% or considerable: 75%-100%.[24]

RESULTS

Search criteria and study characteristics

A summary of the PRISMA flowchart outlining study selection is shown in Figure 1. Following the systematic search, 1380 studies were retrieved for screening. After deduplication and abstract inspection, 50 full-text articles were assessed for eligibility, with 34 reports ultimately excluded. Sixteen reports were deemed acceptable for inclusion, with four included in the manual search. A final total of 20 RCTs satisfied our inclusion criteria and were included in this



Figure 1: PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow diagram summarising retrieved and excluded studies

analysis [Table 1].^[5,25-43] The risk-of-bias analysis for all included studies is summarised in Figure 2. Details on the evidence review for the primary and secondary outcomes can be found in Table 2. A summary of the findings is displayed in Table 3.

Primary outcome: Postoperative pain scores at rest 0-2 h, 10-12 h and 12-24 h

Analysis of the continuous outcomes suggests that the RSB provides a clinically superior analgesic efficacy during the 0-2 h postoperative period when compared to control (SMD = -1.46, 95% CI [-2.04, -0.88], P < 0.001).^[5,25-36,39,40,41,43] Heterogeneity was found to be considerable (I² = 94%, Cochrane Q statistic P < 0.001). At the 10-12 h endpoint, RSB was again deemed effective in minimising postoperative pain scores (SMD -1.02,

95% CI [-1.51, -0.52], P < 0.001),^[25,26,30-34,36-38,41,42] with heterogeneity again being considerable (I² = 95%, Cochrane Q statistic P < 0.001). Finally, in the 12-24 h postoperative period, RSB was found insignificant compared to control at reducing postoperative pain scores (SMD -0.25, 95% CI [-0.55, 0.06], P = 0.11, I² = 83%).^[5,26,29,31,32,34,36,38-42] Heterogeneity was again considerable (I² = 83%, Cochrane Q statistic P < 0.001). Details for each primary endpoint are outlined in Figure 3. Subgroup analyses are available in the attached supplemental data file [SDC Figure 1 and 2].

Secondary Outcome: 24 h IV morphine equivalent consumption

Five studies reported 24-h IV morphine equivalent consumption for nine RSB trial

			Table 1: Cha	racteristics of inc	luded s	tudies		
Study	Group Allocation	Surgical Procedure	Surgical Technique	RSB Technique	RSB Timing	RSB Drug	Control Intervention	Postoperative analgesia
Smith <i>et al</i> ., 1988 ^[25]	RSB (22) Control (24)	Diagnostic gynaecologic laparoscopy	Laparoscopic	Blind loss-of-resistance	Preop	Bupivacaine 0.25%, 30 mL	No intervention	Papaveretum
Azemati <i>et al.</i> , 2005 ^[26]	RSB (30) Control(61)	Diagnostic gynaecologic laparoscopy	Laparoscopic	Blind loss-of-resistance	Postop	Bupivacaine 0.25%, 10 mL	Port-site infiltration or intraperitoneal instillation	Not described
Isaac <i>et al</i> ., 2005 ^[27]	RSB (7) Control (6)	Umbilical hernia repair	Open	Direct insertion	Postop	Bupivacaine 0.25%, 0.15 mL/kg	Local infiltration	Morphine
Gurnaney <i>et al</i> ., 2011 ^[28]	RSB (26) Control (26)	Umbilical hernia repair	Open	Ultrasound-guided	Postop	Bupivacaine 0.25%, adjusted for weight	Local infiltration	Morphine, oxycodone
Dingeman <i>et al</i> ., 2013 ^[29]	RSB (27) Control (25)	Umbilical hernia repair	Open	Ultrasound-guided	Postop	Ropivacaine 0.20%, 0.5 mL/kg	Local infiltration	Ketorolac
Kasem <i>et al</i> ., 2015 ^[30]	RSB (23) Control (22)	LESS Cholecystectomy	Laparoscopic	Ultrasound-guided	Preop	Bupivacaine 0.25%, 20 mL	Port-site infiltration	Lornoxicam, PCA morphine
Hamill <i>et al</i> ., 2015 ^[31]	RSB (73) Control (73)	Laparoscopic appendicectomy	Laparoscopic	Ultrasound-guided	Preop	Bupivacaine 0.25%, adjusted for weight	No intervention	Paracetamol, NSAIDs
Gupta <i>et al</i> ., 2016 ^[32]	RSB (25) Control (50)	Laparoscopic Cholecystectomy	Laparoscopic	Blind loss-of-resistance	Preop	Ropivacaine 0.25%, 30 mL	No intervention or intraperitoneal instillation	Tramadol
Shah <i>et al</i> ., 2016 ^[33]	RSB (30) Control (30)	Laparoscopic tubal ligation	Laparoscopic	Ultrasound-guided	Preop	Bupivacaine 0.25%, 40 mL	No intervention	Tramadol
Chung <i>et al</i> ., 2017 ^[34]	RSB (50) Control (25)	LESS surgery for benign adnexal lesion	Laparoscopic	Ultrasound-guided, surgically guided	Postop	Ropivacaine 0.5%, 20 mL	Sham block	PCA fentanyl
Miyazaki <i>et al</i> ., 2017 ^[5]	RSB (19) Control (19)	LESS Gastrointestinal procedures	Laparoscopic	Laparoscopically guided	Postop	Levobupivacaine 0.25%, 40 mL	No intervention or epidural analgesia	Fentanyl, NSAIDs
Uchinami <i>et al</i> ., 2017 ^[35]	RSB (17) Control (17)	Laparoscopic extraperitoneal closure surgery	Laparoscopic	Ultrasound-guided	Postop	Ropivacaine 0.375%, 0.4 mL/kg	Local infiltration	Not described
Cho <i>et al</i> ., 2018 ^[36]	RSB (30) Control (30)	Laparoscopic extraperitoneal closure surgery	Laparoscopic	Ultrasound-guided	Preop	Ropivacaine 0.25%, 30 mL	No intervention	PCA fentanyl, Ketorolac
Purdy <i>et al</i> ., 2018 ^[37]	RSB (28) Control (12)	Midline laparotomy	Open	Catheter insertion	Postop	Levobupivacaine 0.25%, 0.25 mg/ mL	No intervention	Oxycodone, paracetamol
Kinjo <i>et al</i> ., 2019 ^[38]	RSB (107) Control (101)	Laparoscopy for benign gynaecologic diseases	Laparoscopic	Laparoscopically guided	Postop	Ropivacaine 0.5%, 6 mL/kg	No intervention	Pentazocine, diclofenac, loxoprofen
Suragul <i>et al</i> ., 2022 ^[39]	RSB (52) Control (48)	Laparoscopic Cholecystectomy	Laparoscopic	Direct insertion	Postop	Bupivacaine 0.50%, 5 mL	No intervention	PCA Morphine
Siripruekpong <i>et al</i> ., 2022 ^[40]	RSB (32) Control (34)	Laparoscopic Tubal resection	Laparoscopic	Ultrasound-guided	Postop	Bupivacaine 0.25%, 10 mL	No Intervention	Acetaminophen
Laguduvah <i>et al</i> ., 2022 ^[41]	RSB (50) Control (50)	Midline laparotomy	Laparoscopic	Ultrasound-guided	Postop	Bupivacaine 0.25%, 15 mL	No intervention	Paracetamol, PCA Morphine
Shi <i>et al</i> ., 2023 ^[42]	RSB (30) Control (30)	Radical Gastrectomy	Laparoscopic	Ultrasound-guided	Postop	Ropivacaine 0.40%, 50 mL	Sham Block	PCA Sufentanil, Flurbiprofen axetil
Yörükoğlu et al., 2023 ^[43]	RSB (30) Control (30)	Caesarean Delivery	Open	Linear Probe	Preop	Bupivacaine 0.25%, 20 mL	No intervention	PCA Morphine

PCA=Patient-controlled analgesia; NSAIDs=Non-steroidal anti-inflammatory drugs, RSB=rectus sheath block

comparisons.^[30,32,34,36,37,40-42] Overall, RSB was found to provide superior postoperative consumption of analgesics in contrast to controls after 24 h (SMD = -1.55, 95% CI [-2.35, -0.74], P < 0.001). Heterogeneity was considered considerable (I² = 95%, Cochrane Q statistic P < 0.001). Details regarding secondary



Figure 2: Summary of the revised Cochrane risk-of-bias 2.0 assessment for randomised trials

outcomes can be found in the attached supplemental data file [SDC Figure 3].

Subgroup analysis of primary outcomes: Laparoscopic vs open surgery

Further subgroup analysis suggests that the RSB continues to provide clinically superior analgesic effects independent of the surgical methods employed. During the 0-2 h postoperative outperformed control in both period. RSB open surgery (SMD -0.52, 95% CI [-0.90, -0.13], P < 0.008)^[27-29,43] and laparoscopic surgery (SMD - 1.83, 95% CI [-2.60, -1.08], P < 0.001).^[25,26,30-36,40,41] In the open surgery subgroup, heterogeneity was considered low and not statistically significant ($I^2 = 22\%$, Cochrane Q statistic P = 0.28). In contrast, heterogeneity in the laparoscopic surgery subgroup was considered high and statistically significant ($I^2 = 96\%$, Cochrane Q statistic P < 0.001). A test for subgroup differences found heterogeneity to be high and again statistically significant (I² = 88.7%, Cochrane Q statistic P = 0.003). The details of the subgroup analysis can be found in Figure 3.

Quality of evidence

In the primary outcome, the GRADE quality of evidence was rated as moderate due to inconsistencies in individual study results. For the secondary outcome, the quality of evidence was rated as low due to inconsistencies between trials and a high risk of bias. A high risk of bias arising through deviations from the intended interventions was observed in 1 of 20 (5%) studies.^[32] Additionally, an increased risk of bias was observed in 1 of 20 (5%) studies, arising from missing outcome data.^[25] Each outcome's Funnel plots are also available in the attached supplemental data file [SDC Figures 4-7].

DISCUSSION

The overall findings from this systematic review and meta-analysis show that when the RSB is used compared to reasonable alternative anaesthetic control, it significantly reduces postoperative pain scores up to 12 h following abdominal procedures, with increased effectiveness observed in the first 2 h following surgery. Subgroup analysis of all primary outcomes was not

Table 2: Evidence profile table of rectus sheath block vs control for patients undergoing abdominal surgery. GRADE quality of evidence is reported only when at least three studies report an outcome

Outcomes	Limitations	Inconsistency/ Heterogeneity	Indirectness	Imprecision	Publication bias	Mean difference or odds ratio [95% CI]	Number of participants (studies)	Quality or certainty of the evidence (GRADE)
Pain at rest 0-2 h postoperatively, assessed with VAS score: 0–10 (worst)	No serious limitations	I ² Test for Heterogeneity 94% and <i>P</i> <0.00001	Potential indirectness*	Not detected	Not detected	-1.46 [-2.04, -0.88]	1154 (17 studies) ^(5,25-36,39,40,41,43)	⊕⊕⊕⊖ MODERATE
Pain at rest 10-12 h postoperatively, assessed with VAS score: 0–10 (worst)	No serious limitations	I ² Test for Heterogeneity 93% and <i>P</i> <0.00001	Potential indirectness*	Not detected	Not detected	-1.02 [-1.51, -0.52]	1082 (12 studies) ^{[25,26,30-34,36-38,41,42}	⊕⊕⊕⊖ MODERATE
Pain at rest 12-24 h postoperatively, assessed with VAS score: 0–10 (worst)	No serious limitations	I ² Test for heterogeneity 83% and <i>P</i> <0.00001	Potential indirectness*	Not detected	Not detected	-0.25 [-0.55, 0.06]	1079 (12 studies) ^[5,26,29,31,32,34,36,38-42]	⊕⊕⊕⊖ MODERATE
Oral Morphine equivalent consumption 24 h (mg)	No serious limitations	l ² Test for Heterogeneity 95% and <i>P</i> <0.00001	Potential indirectness*	Not detected	Not detected	-1.55 [-2.35, -0.74]	619 (9 studies) ^[30,33,34,36,37,40-43]	⊕⊕⊕⊖ MODERATE

*Direct evidence consists of research that directly compares the interventions in which we are interested, delivered to the populations in which we are interested and measures outcomes important to patients. Indirectness may be present because patients recruited to studies mostly had non-tissue preserving breast surgery compared to tissue-preserving breast surgery and/or breast surgery with reconstruction likely in modern practice. GRADE=Grading of Recommendations, Assessment, Development and Evaluations; CI=Confidence Interval

		Та	ble 3: Summary	of findings table		
Outcomes	RSB Mean Pain score (SD)	Control Mean Pain score (SD)	Mean difference [95% Confidence Interval]	Number of participants (studies)	Quality or certainty of the evidence (GRADE)	Comments
Pain at rest 0-2 h postoperatively, assessed with VAS score: 0–10 (worst)	2.5 (1.2)	4.2 (1.6)	-1.46 [-2.04, -0.88]	1154 (17 studies) ^[5,25-36, 39,40,41,43]	⊕⊕⊕⊖ MODERATE	High heterogeneity; I ² Test for Heterogeneity 94% and <i>P</i> <0.00001
Pain at rest 10-12 h postoperatively, assessed with VAS score: 0–10 (worst)	2.3 (1.2)	3.3 (1.2)	-1.02 [-1.51, -0.52]	1082 (12 studies) ^[25,26,30-34,36-38,41,42]	⊕⊕⊕⊖ MODERATE	High heterogeneity; I ² Test for Heterogeneity 93% and <i>P</i> <0.00001
Pain at rest 12-24 h postoperatively, assessed with VAS score: 0–10 (worst)	2.3 (1.3)	2.6 (1.2)	-0.25 [-0.55, 0.06]	1079 (12 studies) ^[5,26,29,31,32,34,36,38-42]	⊕⊕⊕⊖ MODERATE	High heterogeneity; I ² Test for Heterogeneity 83% and <i>P</i> <0.00001
Oral Morphine equivalent consumption, 24 h (mg)	8.6 (3.6)	12.9 (4.5)	-1.55 [-2.35, -0.74]	619 (9 studies) ^[30,32,34,36,37,40-43]	⊕⊕⊖⊖ LOW	High heterogeneity; I ² Test for Heterogeneity 95% and <i>P</i> <0.00001

Population: Patients undergoing abdominal surgery; Intervention: Rectus sheath block; Comparator: Control (parenteral analgesia). SD=standard deviation; VAS=visual analogue scale. GRADE (Grading of Recommendations Assessment, Development and Evaluation) Working Group grades of evidence. High certainty: We are very confident that the true effect lies close to that of the estimate of the effect. Moderate certainty: We are moderately confident in the effect estimate. The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. Low certainty: Our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect. Very low certainty: We have very little confidence in the effect estimate. The true effect is likely to differ substantially from the estimate of the effect.

possible due to a limited data set, but subgroup analysis findings within the 0-2 h postoperative period revealed that the analgesic effectiveness of the RSB remains regardless of the choice between open or laparoscopic intervention. Moreover, the use of RSB appears to significantly reduce postoperative opioid use up to 24 h following surgical intervention. Based on our results, the RSB should be considered an effective nerve block consideration for abdominal surgical procedures. Similar findings were demonstrated by Hamid *et al.* in 2021^[7]

itudy or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95	S% CI	IV, Random, 95% CI
l.8.1 Lap 0-2h	10.22	2022	1.222	1000			127222		1000	10.00
zemati 2005 (1)	4.25	2.21	30	4.25	2.21	30	5.3%	0.00 (-0.51, 0	0.51	I
zemati 2005 (2)	4.25	2.21	30	5.25	2.19	31	5.5%	-0.45 [-0.96, 0	1.06]	
no 2018	3.05	1.75	30	4.88	1.95	30	5.5%	-0.67 [-1.19, -0	2.151	1
nung 2017 (1)	2.12	0.33	25	2.0	1.38	25	5.2%	-0.47 [-1.03, 0	1.091	<u> </u>
hung 2017 (2)	2.12	0.73	25	2.6	1.38	25	5.2%	-0.43 [-0.99, 0	2.13	and the second se
upta 2016 (1)	0.5	0.68	25	3.72	1.13	25	4.9%	-3.40 [-4.29, -2	2.51]	~
Supta 2016 (2)	0.5	0.68	25	1.12	0.73	25	5.2%	-0.87 [-1.45, -0	0.28]	~
famill 2015	2.12	0.5	63	3.92	0.5	67	5.2%	-3.58 [-4.14, -3	3.02]	~
Casem 2014	0.25	0.26	23	0.25	0.26	22	5.2%	0.00 (-0.58, 0	0.58]	t
aguduvah 2022	6.25	0.38	50	7.25	0.38	50	5.2%	-2.61 (-3.15, -2	2.07]	~
Miyazaki 2017	1.5	2.05	19	3.4	2.05	19	5.1%	-0.91 [-1.58, -0	0.24]	~
ihah 2016	0	0.1	30	7	0.78	30	2.9%	-12.43 [-14.78, -10	0.07]	
iripruekpong 2022	5.5	2.8	32	6.7	2.3	34	5.3%	-0.46 [-0.95, 0	0.03]	-
mith 1988	0.7	1	22	7.1	1.3	24	4.3%	-5.39 [-6.68, -4	1.10]	
Suragul 2022	5.4	1.2	52	6.2	1.3	48	5.3%	-0.64 [-1.040	0.231	~
Ichinami 2017	0	1.1	17	1	3.7	17	5.1%	-0.36 (-1.04.0	0.321	-
ubtotal (95% CI)			498	-		502	80.0%	-1.73 [-2.43	1.03]	•
leterogeneity: Tau ² =	1.89; 0	:hi ² = 3	329.91,	df = 1	5 (P <	0.000	(); $I^2 = 9$	95%	1000	17.5
est for overall effect:	Z = 4.8	3 (P <	0.0000	01)						
.8.2 Open 0-2h										
Dingerman 2013	0,42	0.65	10	2.61	2.17	19	4,9%	-1.18 [-2.01 -0	0.341	
urnaney 2011	2,36	2.35	26	4	3.14	26	5,2%	-0.58 I-1.14 -0	0.031	-
saac 2005	5.7	1.98	7	5.9	1.39	6	4.6%	-0.11 (-1.20 0	0.981	+
forukoglu 2023	0.1	0.37	30	0.2	0.35	30	5.3%	-0.27 1-0 78	1.231	1
ubtotal (95% CI)			73		0.00	81	20.0%	-0.52 1-0.90 -1	0.131	٨
leterogeneity: Tau ² =	0.04; 0	hi² = 3	3.87, df	= 3 (F	- 0.2	8); 1 ² =	22%	0.52 (0.50, 4		1
lest for overall effect:	Z = 2.6	4 (P =	0.008)							
Total (95% CI)			571			583	100.0%	-1.46 [-2.04, -0	0.88]	•
feterogeneity: Tau ² =	1.59: 0	hi² = ;	342.07.	df = 1	9 (P <	0.0000	$(1); t^2 = 9$	94%	_	to the the
lest for overall effect:	Z = 4.9	5 (P <	0.0000	01)						-10 -5 0 5 10 Envours (PSP) Envours (No PSP)
lest for subgroup diffe	erences	Chi ² =	8.74,	df = 1	(P = 0	.003), 1	' = 88.6%	 A. 140 		
	j	RSB		No	RSB		Ste	d. Mean Difference		Std. Mean Difference
the second se										
Study or Subgroup	Mean	SD	Total	Меап	SD	Total V	Veight	IV, Random, 95% CI	Year	IV, Random, 95% CI
Smith 1988	Mean 1.6	SD 0.58	Total 1 22	Mean 3.2	SD 1.03	Total V 24	Veight 6.1% -	IV, Random, 95% CI	Year 1988	IV, Random, 95% Cl
Smith 1988 Azemati 2005 (1)	Mean 1.6 2.7	SD 0.58 1.22	22 30	Mean 3.2 4	SD 1.03 1.46	70tal V 24 31	Veight 6.1% - 6.4% -	IV, Random, 95% CI 1.86 [-2.56, -1.16] 0.95 [-1.48, -0.42]	Year 1988 2005	IV, Random, 95% Cl
Study or Subgroup Smith 1988 Azemati 2005 (1) Azemati 2005 (2)	Mean 1.6 2.7 2.7	SD 0.58 1.22 1.22	22 30 30	Mean 3.2 4 5	SD 1.03 1.46 1.96	70tal V 24 31 30	Veight 6.1% - 6.4% - 6.4% -	IV, Random, 95% CI 1.86 [-2.56, -1.16] 0.95 [-1.48, -0.42] 1.39 [-1.96, -0.82]	Year 1988 2005 2005	IV, Random, 95% CI
Smith 1988 Azemati 2005 (1) Azemati 2005 (2) Kasem 2014	Mean 1.6 2.7 2.7 2	SD 0.58 1.22 1.22 0.52	Total 22 30 30 23	Mean 3.2 4 5 2.75	SD 1.03 1.46 1.96 0.79	Total V 24 31 30 22	Veight 6.1% - 6.4% - 6.4% - 6.3% -	IV, Random, 95% CI 1.86 [-2.56, -1.16] 0.95 [-1.48, -0.42] 1.39 [-1.96, -0.82] 1.11 [-1.74, -0.48]	Year 1988 2005 2005 2014	IV, Random, 95% Cl
Smith 1988 Smith 1988 Azemati 2005 (1) Azemati 2005 (2) Kasem 2014 Hamill 2015	Mean 1.6 2.7 2.7 2 3.53	SD 0.58 1.22 1.22 0.52 0.5	Total 22 30 30 23 63	Mean 3.2 4 5 2.75 4.25	SD 1.03 1.46 1.96 0.79 0.47	Total V 24 31 30 22 67	Veight 6.1% - 6.4% - 6.4% - 6.3% - 6.7% -	IV, Random, 95% CI 1.86 [-2.56, -1.16] 0.95 [-1.48, -0.42] 1.39 [-1.96, -0.82] 1.11 [-1.74, -0.48] 1.48 [-1.87, -1.09]	Year 1988 2005 2005 2014 2015	IV, Random, 95% Cl
Smith 1988 Azemati 2005 (1) Azemati 2005 (2) Kasem 2014 Hamill 2015 Shah 2016	Mean 1.6 2.7 2.7 2 3.53 1	SD 0.58 1.22 1.22 0.52 0.5 0.01	Total 22 30 30 23 63 30	Mean 3.2 4 5 2.75 4.25 4.67	SD 1.03 1.46 1.96 0.79 0.47 0.78	Total V 24 31 30 22 67 30	Veight 6.1% - 6.4% - 6.4% - 6.3% - 6.7% - 4.7% -	IV, Random, 95% CI 1.86 [-2.56, -1.16] 0.95 [-1.48, -0.42] 1.39 [-1.96, -0.82] 1.11 [-1.74, -0.48] 1.48 [-1.87, -1.09] 6.57 [-7.88, -5.25]	Year 1988 2005 2005 2014 2015 2016	17, Random, 95% Cl
Smith 1988 Azemati 2005 (1) Azemati 2005 (2) Kasem 2014 Hamill 2015 Shah 2016 Gupta 2016 (1)	Mean 1.6 2.7 2.7 2 3.53 1 2.75	SD 0.58 1.22 1.22 0.52 0.5 0.01 1.25	Total 9 22 30 23 63 30 25	Mean 3.2 4 5 2.75 4.25 4.67 3.2	SD 1.03 1.46 1.96 0.79 0.47 0.78 1.68	Total V 24 31 30 22 67 30 25	Veight - 6.1% - 6.4% - 6.3% - 6.7% - 4.7% - 6.4% -	IV, Random, 95% CI 1.86 [-2.56, -1.16] 0.95 [-1.48, -0.42] 1.39 [-1.96, -0.82] 1.11 [-1.74, -0.48] 1.48 [-1.87, -1.09] 6.57 [-7.88, -5.25] 0.30 [-0.86, 0.26]	Year 1988 2005 2005 2014 2015 2016 2016	IV, Random, 95% Cl
Smith 1988 Azemati 2005 (1) Azemati 2005 (2) Kasem 2014 Hamill 2015 Shah 2016 Gupta 2016 (1) Gupta 2016 (2)	Mean 1.6 2.7 2.7 2.3.53 1 2.75 2.75	SD 0.58 1.22 0.52 0.52 0.01 1.25 1.25	Total 22 30 30 23 63 30 25 25 25	Mean 3.2 4 5 2.75 4.25 4.67 3.2 2.84	SD 1.03 1.46 1.96 0.79 0.47 0.78 1.68 0.9	Total V 24 31 30 22 67 30 25 25 25	Veight 6.1% 6.4% 6.3% 6.3% 6.7% 6.7% 6.4% 6.4%	IV, Random, 95% CI 1.86 [-2.56, -1.16] 0.95 [-1.48, -0.42] 1.39 [-1.96, -0.82] 1.11 [-1.74, -0.48] 1.48 [-1.87, -1.09] 6.57 [-7.88, -5.25] -0.30 [-0.86, 0.26] -0.08 [-0.64, 0.47]	Year 1988 2005 2005 2014 2015 2016 2016 2016	IV, Random, 95% Cl
Study or Subgroup Smith 1988 Azemati 2005 (1) Azemati 2005 (2) Kasem 2014 Hamili 2015 Shah 2016 Gupta 2016 (1) Gupta 2016 (2) Chung 2017 (1)	Mean 1.6 2.7 2.7 2.3 3.53 1 2.75 2.75 1.88	SD 0.58 1.22 1.22 0.52 0.5 0.01 1.25 1.25 0.66	Total 22 30 30 23 63 30 25 25 25 25	3.2 4 5 2.75 4.25 4.67 3.2 2.84 2.04	SD 1.03 1.46 1.96 0.79 0.47 0.78 1.68 0.9 0.45	Total V 24 31 30 22 67 30 25 25 25 25	Veight 6.1% - 6.4% - 6.4% - 6.3% - 6.7% - 6.7% - 6.4% 6.4% 6.4%	IV, Random, 95% CI 1.86 [-2.56, -1.16] 0.95 [-1.48, -0.42] 1.39 [-1.96, -0.82] 1.11 [-1.74, -0.48] 1.48 [-1.87, -1.09] 6.57 [-7.88, -5.25] -0.30 [-0.86, 0.26] -0.08 [-0.64, 0.28]	Year 1988 2005 2015 2014 2015 2016 2016 2016 2017	IV, Random, 95% Cl
Study or Subgroup Smith 1988 Azemati 2005 (1) Azemati 2005 (2) Kasem 2014 Hamill 2015 Shah 2016 Gupta 2016 (1) Gupta 2016 (2) Chung 2017 (1) Chung 2017 (2)	Mean 1.6 2.7 2.7 2.3.53 1 2.75 2.75 1.88 2.12	SD 0.58 1.22 1.22 0.52 0.5 0.01 1.25 1.25 0.66 0.88	Total 22 30 30 23 63 30 25 25 25 25 25 25 25	Mean 3.2 4 5 2.75 4.25 4.25 4.67 3.2 2.84 2.04 2.04	SD 1.03 1.46 1.96 0.79 0.47 0.78 1.68 0.9 0.45 0.45	Total V 24 31 30 22 67 30 25 25 25 25 25 25 25	Veight 6.1% - 6.4% - 6.4% - 6.3% - 6.7% - 4.7% - 6.4% 6.4% 6.4% 6.4%	IV, Random, 95% CI 1.86 [-2.56, -1.16] 0.95 [-1.48, -0.42] 1.39 [-1.96, -0.82] 1.11 [-1.74, -0.48] 1.48 [-1.87, -1.09] 6.57 [-7.88, -5.25] -0.30 [-0.86, 0.26] -0.08 [-0.64, 0.47] -0.28 [-0.84, 0.28] 0.11 [-0.44, 0.67]	Year 1988 2005 2015 2014 2015 2016 2016 2016 2016 2017 2017	IV, Random, 95% Cl
Study of Subgroup Smith 1988 Azemati 2005 (1) Azemati 2005 (2) Kasem 2014 Hamili 2015 Shah 2016 Gupta 2016 (1) Gupta 2016 (2) Chung 2017 (1) Chung 2017 (2) Chung 2018	Mean 1.6 2.7 2.7 2.3.53 1 2.75 2.75 1.88 2.12 2	SD 0.58 1.22 1.22 0.52 0.51 1.25 1.25 0.66 0.88 1.47	Total 22 30 30 23 63 30 25 25 25 25 25 30	Mean 3.2 4 5 2.75 4.25 4.67 3.2 2.84 2.04 2.04 2.04 2	SD 1.03 1.46 1.96 0.79 0.47 0.78 1.68 0.9 0.45 0.45 0.98	Total V 24 31 30 22 67 30 25 25 25 25 25 30	Veight 6.1% 6.4% 6.3% 6.7% 6.7% 6.4% 6.4% 6.4% 6.4% 6.4% 6.4% 6.5%	V, Random, 95% CI 1.86 [-2.56, -1.16] 0.95 [-1.48, -0.42] 1.39 [-1.96, -0.82] 1.11 [-1.74, -0.48] 1.14 [-1.87, -1.09] 6.57 [-7.88, -5.25] -0.30 [-0.86, 0.26] -0.08 [-0.64, 0.47] -0.28 [-0.84, 0.42] 0.01 [-0.44, 0.67] 0.00 [-0.51, 0.51]	Year 1988 2005 2014 2015 2016 2016 2016 2017 2017 2017	IV, Random, 95% Cl
Study or Subgroup Smith 1988 Azemati 2005 (1) Azemati 2005 (2) Kasem 2014 Hamill 2015 Shah 2016 Gupta 2016 (1) Gupta 2016 (2) Chung 2017 (2) Chung 2017 (2) Cho 2018 Purdy 2018 (1)	Mean 1.6 2.7 2.7 2.3.53 1 2.75 2.75 1.88 2.12 2 3	SD 0.58 1.22 1.22 0.52 0.51 1.25 1.25 0.66 0.88 1.47 1.6	Total 1 22 30 23 63 30 25 25 25 25 25 25 30 16	Mean 3.2 4 5 2.75 4.25 4.67 3.2 2.84 2.04 2.04 2.04 2.04 3.4	SD 1.03 1.46 1.96 0.79 0.47 0.78 1.68 0.9 0.45 0.45 0.98 2.4	Total V 24 31 30 22 67 30 25 25 25 25 25 25 30 12	Veight 6.1% - 6.4% - 6.4% - 6.3% - 6.7% - 4.7% - 6.4% 6.4% 6.4% 6.4% 6.5% 6.0%	VV.Random, 95% C1 1.86 [-2.56, -1.16] 0.95 [-1.48, -0.42] 1.39 [-1.96, -0.82] 1.48 [-1.87, -1.09] 6.57 [-7.88, -5.25] 0.03 [-0.86, 0.26] -0.08 [-0.64, 0.47] 0.28 [-0.84, 0.28] 0.11 [-0.44, 0.67] 0.02 [-0.29, 0.51]	Year 1988 2005 2005 2014 2015 2016 2016 2016 2017 2017 2018 2018	IV, Random, 95% Cl
Study or Subgroup Smith 1988 Azemati 2005 (1) Azemati 2005 (2) Kasem 2014 Hamill 2015 Shah 2016 Gupta 2016 (2) Chung 2017 (1) Chung 2017 (2) Cho 2018 Purdy 2018 (2)	Mean 1.6 2.7 2.7 2.53 1 2.75 2.75 1.88 2.12 2 3 1 3	SD 0.58 1.22 0.52 0.52 0.01 1.25 1.25 0.66 0.88 1.47 1.6 2.38	Total 22 30 30 23 63 30 25 25 25 25 25 25 30 16 12	Mean 3.2 4 5 2.75 4.25 4.67 3.2 2.84 2.04 2.04 2.04 2.04 3.4 3.4	SD 1.03 1.46 1.96 0.79 0.47 0.78 1.68 0.9 0.45 0.45 0.98 2.4 2.4	Total V 24 31 30 22 67 30 25 25 25 25 25 30 12 12	Veight 6.1% - 6.4% - 6.3% - 6.3% - 6.7% - 4.7% - 6.4% 6.4% 6.4% 6.4% 6.4% 6.5% 6.0% 5.8% -	VV.Random, 95% C1 1.86 [-2.56, -1.16] 0.95 [-1.48, -0.42] 1.39 [-1.96, -0.82] 1.39 [-1.96, -0.82] 1.48 [-1.87, -1.09] 0.30 [-0.86, 0.26] -0.30 [-0.86, 0.26] -0.30 [-0.84, 0.28] 0.11 [-0.44, 0.67] 0.00 [-0.51, 0.51] -0.26 [-0.85, 0.51] -0.26 [-0.95, 0.55]	Year 1988 2005 2005 2014 2015 2016 2016 2017 2017 2017 2018 2018	IV, Random, 95% Cl
Study or Subgroup Smith 1988 Azemati 2005 (1) Azemati 2005 (2) Azemati 2005 (2) Azemati 2005 (2) Gupta 2016 (1) Gupta 2016 (1) Gupta 2016 (2) Chung 2017 (2) Chung 2017 (2) Cho 2018 (1) Purdy 2018 (2) Fund 2019	Mean 1.6 2.7 2.7 2.3.53 1 2.75 2.75 1.88 2.12 2 3 1.3 2.42	SD 0.58 1.22 0.52 0.5 0.01 1.25 1.25 0.66 0.88 1.47 1.6 2.38 1.9	Total 22 30 30 23 63 30 25 25 25 25 25 30 16 12 107	Mean 3.2 4 5 2.75 4.25 4.67 3.2 2.84 2.04 2.04 2.04 2.04 2.4 3.4 2.14	SD 1.03 1.46 1.96 0.79 0.47 0.78 1.68 0.9 0.45 0.45 0.98 2.4 2.4 1.9	Total V 24 31 30 22 67 30 25 25 25 25 25 30 12 12 10	Veight 6.1% 6.4% 6.3% 6.7% 6.7% 6.4% 6.4% 6.4% 6.4% 6.5% 6.0% 5.8%	VV.Random, 95% C1 1.86 [-2.56, -1.16] 0.95 [-1.48, -0.42] 1.39 [-1.96, -0.82] 1.48 [-1.87, -1.09] 6.57 [-7.88, -5.20] 6.57 [-7.88, -5.20] 0.30 [-0.86, 0.26] -0.08 [-0.64, 0.47] 0.28 [-0.84, 0.28] 0.01 [-0.44, 0.67] 0.00 [-0.51, 0.51] 0.02 [-0.95, 0.55] 0.85 [-1.69, -0.01]	Year 1988 2005 2005 2014 2015 2016 2016 2016 2017 2018 2018 2018 2018 2018 2019	IV, Random, 95% Cl
Study or Subgroup Smith 1988 Azemati 2005 (1) Azemati 2005 (2) Kasem 2014 Hamill 2015 Shah 2016 Gupta 2016 (1) Gupta 2016 (2) Chung 2017 (1) Chung 2017 (2) Chung 2017 (2) Chung 2018 (1) Purdy 2018 (2) Kinjo 2019 Londowsh 2022	Mean 1.6 2.7 2.7 3.53 1 2.75 2.75 1.88 2.12 2 3 1.3 2.42 2 3	SD 0.58 1.22 0.52 0.5 0.01 1.25 1.25 0.66 0.88 1.47 1.6 2.38 1.9 0.61	Total 22 30 30 23 63 30 25 25 25 25 25 30 16 12 107 50	Mean 3.2 4 5 2.75 4.25 4.67 3.2 2.84 2.04 2.04 2.04 2.04 2.04 2.4 3.4 3.4 3.2 2.5 4.67 3.2 2.84 2.04 2.04 2.04 2.04 2.04 2.04 2.05 3.2 2.05 3.2 2.05 3.2 2.84 2.05 3.2 2.05 3.2 2.84 2.05 3.2 2.05 3.2 2.05 3.2 2.05 3.2 2.05 3.2 2.05 3.2 2.05 3.2 2.05 3.2 2.05 3.2 2.05 3.2 2.05 3.2 2.05 3.2 2.05 3.2 2.05 3.2 2.05 3.2 2.05 3.2 2.05 3.2 2.05 3.2 2.05 3.2 2.04 2.04 2.04 2.04 2.04 2.04 2.04 2.04 2.04 2.04 2.05 3.2 2.5 3.4 3.2 2.5 3.4 3.2 2.5 3.4 2.5 3.2 2.5 3.4 3.2 2.5 3.4 3.2 2.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3	SD 1.03 1.46 1.96 0.79 0.47 0.78 1.68 0.9 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.9 0.45 0.45 0.9 0.9 0.9 0.45 0.9 0.9 0.9 0.9 0.45 0.9 0.9 0.9 0.9 0.9 0.9 0.9 0.9	Total V 24 31 30 22 67 30 25 25 25 25 25 25 30 12 12 101 50	Veight 6.1% - 6.4% - 6.3% - 6.3% - 6.3% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% - 6.5% - 6.0% - 5.8% - 6.7% -	VV. Random, 95% C1 1.86 [-2.56, -1.16] 0.95 [-1.48, -0.42] 1.39 [-1.96, -0.82] 1.11 [-1.74, -0.48] 1.48 [-1.87, -1.09] 6.57 [-7.88, -5.25] -0.30 [-0.86, 0.26] -0.30 [-0.66, 0.26] -0.30 [-0.64, 0.47] -0.28 [-0.84, 0.63] 0.00 [-0.51, 0.51] -0.20 [-0.95, 0.51] -0.28 [-1.69, -0.01] 0.45 [-0.13, 0.42]	Year 1988 2005 2005 2014 2015 2016 2016 2016 2017 2017 2018 2018 2018 2018 2018 2018 2018	IV, Random, 95% Cl
Study or Subgroup Smith 1988 Azemati 2005 (1) Azemati 2005 (2) Kasem 2014 Hamill 2015 Shah 2016 Gupta 2016 (2) Chung 2017 (1) Chung 2017 (2) Chung 2017 (2) Chung 2017 (2) Chung 2018 (1) Purdy 2018 (2) Kinjo 2019 Laguduvah 2022 Shi 2023	Mean 1.6 2.7 2.7 3.53 1 2.75 2.75 1.88 2.12 2 3 1.3 2.42 3 2.75 2.75 1.88 2.12 2.3 3 1.3 2.42 3 2.75 2.75 3.55	SD 0.58 1.22 0.52 0.52 0.01 1.25 1.25 0.66 0.88 1.47 1.6 2.38 1.9 0.61 0.14	Total 22 30 30 23 63 30 25 25 25 25 25 25 30 16 12 107 50 30	Mean 3.2 4 5 2.75 4.25 4.67 3.2 2.84 2.04 2.04 2.04 2.04 2.04 2.04 2.4 3.4 3.4 2.14 3.25 4	SD 1.03 1.46 1.96 0.79 0.47 0.78 1.68 0.9 0.45 0.98 0.45 0.99 0.45 0.98 0.45 0.99 0.45 0.98 0.45 0.99 0.45 0.99 0.45 0.99 0.45 0.99 0.45 0.99 0.45 0.99 0.45 0.99 0.45 0.99 0.45 0.99 0.45 0.99 0.99 0.99 0.45 0.99 0.90 0.9	Total V 24 31 30 22 67 30 25 25 25 25 25 25 25 25 25 25 25 10 12 101 50 30	Veight 6.1% - 6.4% - 6.4% - 6.3% - 6.7% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% - 5.4% - 6.4% - 5.4% - 6.4% - 5.5% - 6.5% - 5.8% - 6.7% - 6.7% - 6.7% - 6.7% - 6.7% - 6.7% - 6.7% - 6.7% -	VV.Random, 95% C1 1.86 [-2.56, -1.16] 0.95 [-1.48, -0.42] 1.39 [-1.96, -0.82] 1.39 [-1.96, -0.82] 1.48 [-1.87, -1.09] 0.57 [-7.88, -5.25] -0.30 [-0.86, 0.26] -0.38 [-0.64, 0.47] 0.11 [-0.44, 0.67] 0.00 [-0.51, 0.51] -0.26 [-0.84, 0.28] 0.11 [-0.44, 0.67] 0.00 [-0.51, 0.51] -0.20 [-0.95, 0.55] 0.85 [-1.69, -0.01] 0.15 [-0.13, 0.42] -0.32 [-0.72, 0.07]	Year 1988 2005 2015 2016 2016 2016 2016 2016 2017 2018 2018 2018 2018 2018 2018 2018 2018	IV, Random, 95% Cl
Study or Subgroup Smith 1988 Azemati 2005 (1) Azemati 2005 (2) Kasem 2014 Hamill 2015 Shah 2016 Gupta 2016 (2) Chung 2017 (1) Chung 2017 (2) Cho 2018 Purdy 2018 (1) Purdy 2018 (2) Kinjo 2019 Laguduvah 2022 Shi 2023 Total (95% Ch	Mean 1.6 2.7 3.53 1 2.75 2.75 1.88 2.12 3 1.3 2.42 3 2.75	SD 0.58 1.22 0.52 0.5 0.01 1.25 0.66 0.88 1.47 1.6 2.38 1.9 0.61 0.14	Total 22 30 30 23 63 30 25 25 25 25 30 16 12 107 50 30	Mean 3.2 4 5 2.75 4.25 4.67 3.2 2.84 2.04 2.04 2.04 2.04 3.4 3.4 2.14 3.25 4	SD 1.03 1.46 1.96 0.79 0.47 0.78 1.68 0.9 0.45 0.45 0.98 2.4 2.4 1.9 0.9 0.61	Total V 24 31 30 22 67 30 25 25 25 25 25 30 12 12 101 50 30	Veight 6.1% - 6.4% - 6.4% - 6.3% - 6.7% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% - - - 6.4% - - - 6.4% - - - 6.4% - - - 6.4% - - - 6.5% - - - - 6.5% - - - - 6.7% - - - - 6.7% - - - - 6.1% - - - -	VV.Random, 95% C1 1.86 [-2.56, -1.16] 0.95 [-1.48, -0.42] 1.39 [-1.96, -0.82] 1.39 [-1.96, -0.82] 1.48 [-1.87, -1.09] 6.57 [-7.88, -5.25] -0.30 [-0.86, 0.26] -0.08 [-0.64, 0.28] 0.11 [-0.44, 0.67] 0.00 [-0.51, 0.51] -0.20 [-0.95, 0.55] 0.85 [-1.69, -0.13, 0.42] -0.35 [-0.72, 0.07] 2.79 [-3.51, -2.07]	Year 1988 2005 2015 2016 2016 2016 2016 2017 2017 2018 2018 2018 2018 2019 2022 2023	IV, Random, 95% Cl
Study or Subgroup Smith 1988 Azemati 2005 (1) Azemati 2005 (2) Kasem 2014 Hamill 2015 Shah 2016 Gupta 2016 (2) Chung 2017 (1) Chung 2017 (2) Chung 2017 (2) Chung 2017 (2) Chung 2018 (1) Purdy 2018 (2) Kinjo 2019 Laguduvah 2022 Shi 2023 Total (95% CI)	Mean 1.6 2.7 2 3.53 1 2.75 2.75 2.75 2.75 1.88 2.12 2 3 1.3 2.42 3 2.75 0.92; C	SD 0.58 1.22 0.52 0.5 0.01 1.25 0.66 0.88 1.47 1.6 2.38 1.9 0.61 0.14 hi ² = 2	Total 22 30 30 23 63 30 25 25 25 25 25 30 16 12 107 50 30 543 207.28.	Mean 3.2 4 5 2.75 4.25 4.67 3.2 2.84 2.04 2.04 2.04 2.04 2.04 2.14 3.4 3.4 3.4 4.25 4 4 4 4 4 5 4 4 5 4 4 5 4 4 5 4 4 5 5 4 4 5 4 4 5 5 4 4 5 5 4 4 5 5 4 4 5 5 4 4 5 5 4 4 5 5 4 4 5 5 4 4 5 5 4 2 5 4 4 5 5 4 2 5 4 5 4 5 4 5 4 5 4 4 5 4 4 5 4 4 5 4 4 5 4 4 5 4 4 5 4 4 5 4 4 5 4 4 5 4 4 5 4 4 5 4 4 5 4 4 5 5 4 4 5 5 4 4 5 5 4 4 5 5 4 4 5 5 4 4 5 5 4 4 5 5 5 4 4 5 5 4 4 5 5 5 4 4 5 5 5 5 5 5 5 5 5 5 5 5 5	SD 1.03 1.46 1.96 0.79 0.47 0.78 1.68 0.9 0.45 0.45 0.98 2.4 2.4 1.9 0.9 0.61	Total V 24 31 30 22 67 30 25 25 25 25 25 25 25 25 25 30 12 12 101 50 30 539 1 0.00000	Veight 6.1% - 6.4% - 6.3% - 6.3% - 6.3% - 6.7% - 4.7% - 6.4% 6.4% - 6.4% 6.4% 6.4% - - 6.4% 6.4% - - 6.4% 6.5% - - 6.5% - - - 6.8% - - - 6.1% - - - 6.1% - - - 6.1% - - - 00.0% - - - 1); l ² = - -	VV.Random, 95% C1 1.86 [-2.56, -1.16] 0.95 [-1.48, -0.42] 1.39 [-1.96, -0.82] 1.39 [-1.96, -0.82] 1.48 [-1.87, -1.09] 6.57 [-7.88, -5.25] -0.30 [-0.64, 0.24] -0.38 [-0.64, 0.24] 0.01 [-0.44, 0.67] 0.00 [-0.51, 0.51] -0.20 [-0.95, 0.55] 0.85 [-1.69, -0.01] 0.35 [-0.13, 0.42] -0.32 [-0.72, 0.07] 2.79 [-3.51, -2.07] -1.02 [-1.51, -0.52] %	Year 1988 2005 2005 2014 2015 2016 2016 2016 2017 2017 2017 2017 2018 2018 2018 2019 2022 2023	IV, Random, 95% Cl
Study or Subgroup Study or Subgroup Azemati 2005 (1) Azemati 2005 (2) Kasem 2014 Hamill 2015 Shah 2016 Gupta 2016 (2) Chung 2017 (1) Chung 2017 (2) Cho 2018 Purdy 2018 (1) Purdy 2018 (2) Kinjo 2019 Laguduvah 2022 Shi 203 Total (95% C) Hestrogeneity: Tau ² = Test for overall effect:	Mean 1.6 2.7 3.53 1 2.75 1.88 2.12 3 1.3 2.75 0.92: CZ 2	SD 0.58 1.22 1.22 0.52 0.51 1.25 1.25 0.61 0.14 hi² = 2 0.14	Total (22 30 23 63 30 25 25 25 25 25 25 30 16 12 107 50 30 543 :07.28, 0.0001	Mean 3.2 4 5 2.75 4.67 3.2 2.84 2.04 2 3.4 3.4 2.14 3.25 4 df = 1	SD 1.03 1.46 1.96 0.79 0.47 0.78 1.68 0.9 0.45 0.45 0.45 0.45 0.45 0.45 0.45 0.98 2.4 1.9 0.98 2.4 1.9 0.98 0.98 2.4 1.9 0.98 0.99 0.98 0.98 0.98 0.98 0.99 0.98 0.98 0.99 0.98 0.98 0.99 0.98 0.98 0.99 0.98 0.98 0.99 0.98 0.99 0.98 0.98 0.99 0.98 0.99 0.98 0.99 0.98 0.99 0.98 0.99 0.98 0.99 0.98 0.99 0.98 0.99 0.98 0.99 0.98 0.99 0.98 0.99 0.98 0.99 0.98 0.99 0.98 0.99 0.9	Total V 24 31 30 22 67 30 25 25 25 25 25 25 30 12 12 12 101 50 30 539 1 0.00000	Veight 6.1% - 6.4% - 6.3% - 6.3% - 6.7% - 6.7% - 4.7% - 6.4% - 6.4% - 6.4% - - - 6.4% - - - 6.4% - - - 6.4% - - - 6.5% - - - 6.7% - - - 6.7% - - - 6.7% - - - 6.7% - - - 6.1% - - - 0.00% - - - $1)$: 1^2 93 - -	VV. Random, 95% C1 1.86 [-2.56, -1.16] 0.95 [-1.48, -0.42] 1.39 [-1.96, -0.82] 1.39 [-1.96, -0.82] 1.48 [-1.87, -1.09] 6.57 [-7.88, -5.25] -0.30 [-0.64, 0.24] -0.38 [-0.64, 0.28] 0.11 [-0.44, 0.67] -0.28 [-0.84, 0.28] 0.11 [-0.44, 0.67] 0.00 [-0.51, 0.51] -0.20 [-0.95, 0.55] 0.85 [-1.69, -0.01] 2.79 [-3.51, -2.07] -1.02 [-1.51, -0.52] %	Year 1988 2005 2014 2015 2016 2016 2016 2016 2017 2017 2018 2018 2018 2018 2018 2019 2022 2023	IV, Random, 95% CI
Study or Subgroup Smith 1988 Azemati 2005 (1) Azemati 2005 (2) Kasem 2014 Hamill 2015 Shah 2016 Gupta 2016 (2) Chung 2017 (1) Chung 2017 (2) Cho 2018 Purdy 2018 (2) Kinjo 2019 Laguduvah 2022 Shi 2023 Total (95% C) Heterogeneity: Tau ² = Test for overall effect:	Mean 1.6 2.7 2.7 2.75 2.75 1.8 2.75 2.83 2.12 2 3 2.42 3 2.75 0.92: C Z 4.0	SD 0.58 1.22 0.5 1.22 0.5 0.01 1.25 1.25 0.66 0.61 0.61 0.61 0.61 0.14	Total (22 30 23 63 30 25 25 25 25 25 25 30 16 12 107 50 30 543 .07.28, 0.0001	Mean 3.2 4 5 2.75 4.25 4.25 4.25 4.25 3.2 2.84 2.04 2.04 2.04 2.04 2.04 2.14 3.4 2.14 3.25 4 df 4 df 1 2.15 4 df 1 2.15 4 2.75 4 4 2.05 4 4 2.05 4 4 4 1 2 2.84 2.15 4 4 1 2 2.84 2.15 4 4 1 2 2.84 2.15 4 4 1 2 2 2 4 4 2 2 4 4 2 2 4 4 2 2 4 4 2 2 4 4 2 2 4 4 2 2 4 4 2 2 4 4 2 2 4 4 2 4 4 2 4 4 2 4 4 2 4 4 2 4 4 2 4 4 3 4 2 4 4 3 4 2 4 4 3 4 2 4 4 3 4 2 5 4 4 3 4 4 3 4 4 3 4 4 3 4 4 3 4 4 3 4 4 3 4 4 3 4 4 3 4 4 3 4 4 3 4 4 3 4 4 3 4 4 4 3 4 4 4 3 4 4 3 4 4 3 4 4 3 4 4 4 3 4 4 4 4 4 4 4 4 4 4 4 4 4	SD 1.03 1.46 0.79 0.47 0.78 1.68 0.9 0.47 0.9 0.47 0.9 0.45 0.98 2.4 2.4 1.9 0.61 5 (P <	Total V 24 31 30 22 67 30 25 25 25 25 25 25 25 25 25 25 25 25 25	Veight 6.1% - 6.4% - - 6.4% - 6.4% - -	VV. Random, 95% C1 1.86 [-2.56, -1.16] 0.95 [-1.48, -0.42] 1.39 [-1.96, -0.82] 1.39 [-1.96, -0.82] 1.48 [-1.87, -1.09] 6.57 [-7.88, -5.25] -0.30 [-0.64, 0.47] 0.01 [-0.44, 0.67] 0.02 [-0.86, 0.26] 0.01 [-0.44, 0.67] 0.02 [-0.51, 0.51] -0.20 [-0.95, 0.55] 0.85 [-1.69, -0.01] 2.79 [-3.51, -2.07] -1.02 [-1.51, -0.52] %	Year 1988 2005 2014 2015 2016 2016 2016 2017 2018 2018 2018 2018 2018 2019 2022 2023	IV, Random, 95% CI
Study or Subgroup Smith 1988 Azemati 2005 (1) Azemati 2005 (2) Kasem 2014 Hamill 2015 Shah 2016 (2) Gupta 2016 (2) Chung 2017 (1) Chung 2017 (2) Cho 2018 (2) Kinjo 2019 Laguduvah 2022 Shi 2023 Total (95% C) Heterogeneity: Tau ² = Test for overall effect:	Mean 1.6 2.7 2.7 2.75 1.2.75 2.75 1.33 2.12 2 3 2.12 2 3 2.42 3 2.75 0.92: CZ	SD 0.58 1.22 0.52 0.52 0.51 1.25 0.661 0.14 hi ^d = 2 0.0 (P <	Total (22 30 23 63 30 25 25 25 25 25 30 16 12 107 50 30 543 :07.28, 0.0001	Mean 3.2 4 5 2.75 4.25 3.2 2.84 2.04 2.04 2.04 2.04 2.04 2.04 3.4 3.4 3.4 4.67 4.7 4.7 4.7 4.7 4.7 4.7 4.7 4.	SD 1.03 1.46 1.96 0.79 0.47 0.78 0.45 0.45 0.45 0.45 0.98 2.4 2.4 1.9 0.9 0.9 0.58 2.4 5 (P <	Total V 24 31 30 22 67 30 25 25 25 25 25 25 25 25 25 25 25 25 25	Veight 6.1% - 6.4% - 6.4% - 6.4% - 6.3% - 6.7% - - - 4.7% - 6.4% - 6.4% - - - 6.4% - - - 6.4% - - - 6.5% - - - 6.5% - - - 6.5% - - - 6.5% - - - 6.5% - - - 6.1% - - - $0.0.0\%$ - - - $1)$; 1^2 = 93 -	IV. Random, 95% CI. 1.86 [-2.56, -1.16] 0.95 [-1.48, -0.42] 1.39 [-1.96, -0.82] 1.39 [-1.96, -0.82] 1.48 [-1.87, -1.09] 6.57 [-7.88, -5.25] -0.30 [-0.68, 0.26] -0.08 [-0.64, 0.47] 0.00 [-0.51, 0.40] 0.01 [-0.44, 0.67] 0.00 [-0.51, 0.51] -0.22 [-0.95, 0.55] 0.85 [-1.69, -0.01] 2.79 [-3.51, -2.07] -1.02 [-1.51, -0.52] %	Year 1988 2005 2005 2014 2016 2016 2016 2016 2017 2017 2017 2018 2018 2018 2018 2018 2018	IV, Random, 95% CI
Study or Subgroup Study or Subgroup Azemati 2005 (1) Azemati 2005 (2) Kasem 2014 Hamill 2015 Shah 2016 Gupta 2016 (1) Gupta 2016 (2) Chung 2017 (2) Chung 2017 (2) Chung 2017 (2) Chung 2017 (2) Chung 2018 (1) Purdy 2018 (2) Kinjo 2019 Lagoduvah 2022 Shi 2023 Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: :	Mean 1.6 2.7 2.3 3.53 1 2.75 2.75 1.88 2.12 3 1.3 2.75 0.92: CZ 2 4.0	SD 0.58 1.22 0.52 0.52 0.52 0.51 1.25 0.66 0.88 1.9 0.61 1.47 1.6 2.38 1.9 0.61 0.14 hi ^a = 2 RSB c	Total (22 30 30 23 33 25 25 25 25 25 30 16 12 107 30 543 :07.28, 0.0001	Mean 3.2 4 5 2.75 4.25 4.25 4.25 2.84 2.04 2 2.84 2.04 2 3.4 2.14 3.2 4 df = 1!	SD 1.03 1.46 1.96 0.79 0.47 0.78 0.45 0.45 0.45 0.98 2.4 1.9 0.9 0.61 5 (P <	Total V 24 31 30 22 67 30 25 25 25 25 25 25 25 30 12 12 101 50 30 539 1 0.00000	Veight 6.1% - 6.4% - 6.4% - 6.4% - 6.3% - 6.3% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% - 5.8% - 6.3% - 6.7% - 6.3% - 6.7% - 6.3% - 10% - 6.4% - 5.8% - 6.7% - 1% - 00.00% - 11); I ² = 93 93	VV. Random, 95% C1 1.86 [-2.56, -1.16] 0.95 [-1.48, -0.42] 1.39 [-1.96, -0.82] 1.48 [-1.87, -1.09] 6.57 [-7.88, -5.25] 0.08 [-0.64, 0.47] 0.30 [-0.86, 0.26] -0.08 [-0.84, 0.28] 0.011 [-0.44, 0.67] 0.02 [-0.55, 0.55] 0.85 [-1.69, -0.01] 0.15 [-0.13, 0.42] -0.32 [-0.72, 0.07] 2.79 [-3.51, -2.07] 1.02 [-1.51, -0.52] %	Year 1988 2005 2015 2014 2016 2016 2016 2016 2017 2017 2017 2018 2018 2018 2018 2019 2022 2022 2023	IV, Random, 95% Cl
Study or Subgroup Study or Subgroup Azemati 2005 (1) Azemati 2005 (2) Kasem 2014 Hamill 2015 Shah 2016 Gupta 2016 (1) Gupta 2016 (2) Chung 2017 (1) Chung 2017 (2) Cho 2018 Purdy 2018 (2) Kinjo 2019 Purdy 2018 (2) Kinjo 2019 Chung 2017 (2) Chung 2017 (2)	Mean 1.6 1.7 2.7 2.7 2.7 2.75 2.75 2.75 2.75 2.75 2.72 2.3 3.3 2.42 2 3.2.42 2 3.2.75 0.92: C Z = 4.0 Mean	SD 0.58 1.22 1.22 0.52 0.51 1.25 0.61 0.14 hi ⁰ = 2 0.014 RSB SCB	Total (22 300 23 30 25 25 25 25 25 30 16 12 107 50 30 12 107 50 30 07.28, 0.0001	Mean 3.2 4 5 2.75 4.25 4.67 3.2 2.84 2.04 2 3.4 3.4 3.4 3.4 3.4 4.25 4 df = 1:)	SD 1.03 1.46 1.96 0.79 0.47 0.79 0.47 0.92 0.43 0.93 2.4 2.4 2.4 0.9 0.61 5 (P <	Total V 24 31 30 22 67 30 25 25 25 25 25 25 25 25 25 25 25 25 25	Veight 6.1% - 6.4% - 6.4% - 6.4% - 6.3% - 6.7% - 6.4% - 6.4% - 5.4% - 6.4% - 5.4% - 6.4% - 5.4% - 6.4% - 5.8% - 6.3% - - - 6.3% - - - 6.3% - - - 6.3% - - - 6.3% - - - 6.1% - - - 93 - - -	VV, Random, 95% C1 1.86 [-2.56, -1.16] 0.95 [-1.48, -0.42] 1.39 [-1.96, -0.82] 1.39 [-1.96, -0.82] -0.30 [-0.86, 0.26] -0.30 [-0.86, 0.26] -0.30 [-0.86, 0.26] -0.30 [-0.86, 0.26] -0.28 [-0.84, 0.28] 0.11 [-0.44, 0.67] 0.00 [-0.51, 0.51] -0.20 [-0.95, 0.55] 0.35 [-1.69, -0.07] 2.79 [-0.51, -2.07] -1.02 [-1.51, -0.52] % Std. Mean Different tt. VK, Random, 95 -0.24 [-0.42] -0.24 [-0.42] -0.24 [-0.42] -0.42] -0.42 [-0.42] -0.42 [-0.	Year 1988 2005 2005 2014 2016 2016 2016 2016 2017 2018 2018 2018 2018 2019 2022 2023 	IV, Random, 95% CI
Study or Subgroup Smith 1988 Azemati 2005 (1) Azemati 2005 (2) Kasem 2014 Hamill 2015 Shah 2016 Gupta 2016 (1) Gupta 2016 (2) Chung 2017 (2) Chung 2017 (2) Chung 2017 (2) Chung 2017 (2) Chung 2018 (1) Purdy 2018 (2) Kinjo 2019 Lagudtvah 2022 Shi 2023 Total (95% CI) Heterogeneity: Tau ² = Test for overall effect : Study or Subgroup Azemati 2005 (1)	Mean 1.6 1.6 2.7 2.7 2.7 3.53 1 2.75 1.88 2.12 2 3 1.3 2.42 3 2.42 3 2.42 3 2.75 0.92: C 0.92: C Z 4.00 Mean	SD 0.58 1.22 0.52 0.52 0.51 1.25 1.25 1.25 1.25 1.25 0.66 0.88 1.47 1.6 0.61 0.14 hill 2.38 1.9 0.14 1.9 1.19 1.19 1.19 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25	Total 1 22 30 30 30 23 30 30 23 30 25 25 25 25 30 16 12 107 50 30 07.28, 0.0001	Mean 3.2 4 5 2.75 4.25 3.2 2.84 2.04 2.04 2.04 2.04 2.04 2.14 3.25 4 df = 1:)	SD 1.03 1.046 1.96 0.79 0.47 0.78 1.68 0.93 2.4 1.9 0.45 0.93 1.146	Total V 24 31 31 31 30 22 67 30 25 25 25 25 30 12 101 50 50 30 539 10 6 3 6 3	Veight 6.1% - 6.4% - 6.4% - 6.4% - 6.7% - 6.7% - 4.7% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% 6.4% - - 6.7% - - - 6.7% - - - 6.7% - - - 6.7% - - - 6.7% - - - 6.7% - - - 6.7% - - - $1); l^2 = 93$ - - - 4 Weight - - -	VV. Random, 95% C1 1.36 [-2.56, -1.16] 0.95 [-1.48, -0.42] 1.39 [-1.96, -0.82] 1.39 [-1.96, -0.82] 1.31 [-1.74, -0.48] 1.48 [-0.37, -1.09] 6.57 [-7.88, -5.25] -0.30 [-0.68, 0.26] -0.38 [-0.64, 0.47] 0.30 [-0.51, 0.51] 0.31 [-0.44, 0.67] 0.30 [-0.51, 0.51] 0.32 [-0.72, 0.07] 2.79 [-3.51, -2.07] 1.02 [-1.51, -0.52] % Std. Mean Different VV, Random, 95 ~-0.22 [-0.73, 0.42]	Year 1988 2005 2005 2014 2015 2016 2016 2016 2016 2016 2017 2018 2018 2019 2022 2023 	IV, Random, 95% CI
Study or Subgroup Study or Subgroup Azemati 2005 (1) Azemati 2005 (2) Kasem 2014 Hamill 2015 Shah 2016 Gupta 2016 (1) Gupta 2016 (2) Chung 2017 (1) Chung 2017 (2) Chung 2017 (2) Chung 2018 (1) Purdy 2018 (2) Kinjo 2019 Lagudwah 2022 Sha 2023 Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: 3 Study or Subgroup Azemati 2005 (1) Azemati 2005 (2)	Mean 1.6 2.7 2.7 3.53 1 2.75 2.75 2.75 2.88 2.12 3 1.3 2.42 3 2.42 3 0.92: C Z = 4.0 Mean Mean	SD 0.58 1.22 0.52 0.52 0.52 0.52 0.52 0.52 0.52 0.52 0.52 0.52 0.52 0.52 0.52 0.52 0.52 0.61 0.14 hi² = 2 0.61 0.14 hi² = 2 1.22	Total 1 22 30 30 30 23 30 23 63 30 25 25 25 25 30 107 50 30 30 543 0.0001 0.007.28, 0.0001 30 2 30 30 30	Mean 3.2 4 5 2.75 4.25 4.25 4.25 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.4 2.84 4.67 3.4 2.84 4.67 3.4 2.84 4.67 3.4 2.84 4.67 3.4 2.84 4.67 3.4 2.84 4.67 3.4 2.84 4.67 3.4 2.84 4.67 3.4 2.84 4.67 3.4 2.84 4.87 4.77 4	SD 1.03 1.046 1.96 0.79 0.47 0.78 1.68 0.9 0.45 0.45 0.45 0.45 0.90 0.61 5 (P <	Total V 24 31 30 22 25 25 25 25 25 25 25 25 25 25 25 25	Veight 6.1% - 6.1% - 6.4% - 6.4% - 6.4% - 6.7% - - - 6.4% - 6.4% - 6.4% - - - 6.4% - - - 6.4% - - - 6.4% - - - 6.4% - - - 6.5% - - - 6.1% - - - 6.1% - - - 6.1% - - - 6.1% - - - 1): I ² = 93 - - - 4 Weight - - 0 - 5.5% -	IV, Random, 95% CI 1.86 [-2.56, -1.16] 0.95 [-1.48, -0.42] 1.39 [-1.96, -0.82] 1.39 [-1.96, -0.82] 0.30 [-0.86, 0.26] -0.30 [-0.86, 0.26] -0.30 [-0.86, 0.26] -0.30 [-0.86, 0.26] -0.30 [-0.86, 0.26] -0.30 [-0.86, 0.26] 0.30 [-0.51, 0.51] -0.30 [-0.51, 0.51] -0.30 [-0.52, 0.53] 0.35 [-1.69, -0.01] 0.35 [-1.69, -0.01] 0.35 [-1.67, -0.01] 0.35 [-1.51, -2.07] 1.102 [-1.51, -0.52] % Std. Mean Different tt. V, Random, 95 % -0.27 [-0.73, 0.73]	Year 1988 2005 2005 2005 2014 2015 2016 2016 2017 2017 2017 2017 2017 2017 2017 2018 2018 2018 2019 2022 2023	IV, Random, 95% CI
Study or Subgroup Study or Subgroup Azemati 2005 (1) Azemati 2005 (2) Kasem 2014 Hamill 2015 Shah 2016 (1) Gupta 2016 (2) Chung 2017 (1) Chung 2017 (2) Cho 2018 Purdy 2018 (1) Purdy 2018 (2) Kinjo 2019 Laguduvah 2022 Shi 2023 Total (95% C) Heterogeneity: Tau ² = Test for overall effect: : Study or Subgroup Azemati 2005 (2) Cho 2018	Mean 1.6 2.7 2.7 2.3.53 1.7 2.75 2.75 2.75 2.12 2.12 2.12 2.13 2.42 3 3.2.75 0.92: C Z = 4.0 Mean 2.7, 2.7 2.7 2.7 2.15 1.3 2.42 2.15 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.	SD 0.58 0.52 0.52 1.22 1.22 0.52 0.53 0.52 0.53 0.52 0.53 0.53 0.61 0.14 hi ² = 2 0.61 0.14 hi ² = 2 1.25 1.25 1.25 1.25 1.26 1.27 1.28 1.29 1.20 1.22 0.14	Total 1 22 30 30 30 23 30 23 30 25 25 25 25 25 25 30 16 12 30 50 30 543 107 543 0.0001 50 30 25 50 30 25 50 30 26 30 25 25 50 30 26 50 30 26 50 30 26 50 30 26 50 30 30	Mean 3.2 4 5 2.75 4.25 4.25 4.25 2.04 2.04 2.04 2.04 2.04 2.14 3.4 3.4 4 4 1 Mea	SD 1.03 1.03 1.03 1.46 1.96 0.79 0.47 0.78 0.45 0.98 2.4 2.4 1.9 0.61 5 (P <	Total V 24 24 31 31 30 22 67 30 25 25 30 12 12 12 101 50 539 1 50 539 58 D D Total 6 3 8 3 8 3	Veight 6.1% - $6.1%$ - 6.4% - 6.4% - 6.7% - 6.7% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% - - - 6.4% - - - 6.4% - - - 6.4% - - - 6.4% - - - 6.4% - - - 6.4% - - - 6.7% - - - 6.1% - - - $1); l^2 = 93$ - - - 0.6550 - - - 0.6550 - - -	VV. Random, 95% C1 1.36 [-2.56, -1.16] 0.95 [-1.48, -0.42] 1.39 [-1.96, -0.82] 1.39 [-1.96, -0.82] 1.31 [-1.74, -0.48] 1.48 [-0.64, -0.82] 0.57 [-7.88, -5.25] -0.30 [-0.66, 0.26] -0.38 [-0.64, 0.42] 0.11 [-0.44, 0.67] 0.00 [-0.51, 0.51] -0.22 [-0.72, 0.07] 2.79 [-3.51, -2.07] 1.02 [-1.51, -0.52] % Std. Mean Different V, Random, 95 ~ -0.22 [-0.73, 6 ~ -0.22 [-0.73, 6 ~ 0.20 [-0.75, 6	Year 1988 2005 2005 2015 2016 2016 2016 2017 2018 2018 2018 2018 2018 2018 2018 2018	IV, Random, 95% Cl
Study or Subgroup Smith 1988 Azemati 2005 (1) Azemati 2005 (2) Kasem 2014 Hamill 2015 Shah 2016 Gupta 2016 (1) Gupta 2016 (2) Chung 2017 (1) Chung 2017 (2) Cho 2018 Purdy 2018 (2) Kinjo 2019 Laguduvah 2022 Shi 2023 Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: . Study or Subgroup Azemati 2005 (1) Azemati 2005 (2) Cho 2018 Chung 2017 (1)	Mean 1.6 2.7 2.7 2.3 3.53 1.1 2.75 1.88 2.12 2.75 1.38 2.75 1.32 1.32 2.75 1.32 1.32 2.75 1.32 1.32 1.32 2.75 1.32 1.52 1.68 1.68 1.52 1.52 1.52 1.52 1.58	SD 0.58 0.58 0.58 1.22 1.22 1.22 1.22 0.58 0.50 0.51 1.25 0.66 0.88 1.9 0.61 0.61 0.62 0.62 0.64 0.61 0.61 0.62 0.62 1.25 0.62 0.61 0.61 0.14 hi² = 2 0.62 1.25 0.61 0.61 0.62 1.25 0.93 0.93 1.062	Total 1 222 30 30 30 23 63 30 23 63 30 25 25 25 25 30 167 50 167 50 5643 9 Total 23 30 25 533 9 Total 23 30	Mean 3.2 4 5 2.75 4.67 3.4 4.25 4.67 3.2 2.04 2.04 2.04 2.04 2.04 2.04 2.04 2.04 3.4 3.4 3.4 3.4 4 4 df = 1!) 1 1.1 1.9 1.9	SD .1.03 1.03 1.46 1.96 0.79 0.78 1.68 0.79 0.45 0.45 0.99 2.4 2.4 2.4 1.9 0.90 0.61 5 (P <	Total ¥ 24 24 31 30 67 67 67 67 67 67 25 25 25 25 25 25 25 25 25 25 25 25 25	Veight 6.1% - 6.1% - 6.4% - 6.4% - 6.4% - 6.3% - 6.7% - 4.7% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% 6.4% - - 6.7% - - - 6.7% - - - 00.0% - - - 1): 1 ² 93 - - 0 6.51 - - 0 6.55 - - 0 6.55 - -	VV, Random, 95% CI 1.86 [-2.56, -1.16] 0.95 [-1.48, -0.42] 1.39 [-1.96, -0.82] 1.39 [-1.96, -0.82] 0.30 [-0.86, 0.26] -0.30 [-0.86, 0.26] -0.30 [-0.86, 0.26] -0.30 [-0.86, 0.26] -0.30 [-0.86, 0.26] -0.30 [-0.86, 0.26] -0.30 [-0.51, 0.51] -0.30 [-0.51, 0.51] -0.32 [-0.72, 0.07] 0.35 [-1.69, -0.01] 0.35 [-1.69, -0.01] 0.35 [-1.51, -0.52] % Std. Mean Different t/ V, Random, 95 % -0.27 [-0.73, 0. % 0.02 [-0.51, -0.52]	Year 1988 2005 2005 2014 2015 2016 2016 2017 2018 2017 2018 2017 2018 2017 2018 2019 2022 2023 2023 2023	IV, Random, 95% CI
Study or Subgroup Study or Subgroup Azemati 2005 (1) Azemati 2005 (2) Kasem 2014 Hamill 2015 Shah 2016 (1) Gupta 2016 (2) Chung 2017 (1) Chung 2017 (2) Cho 2018 Purdy 2018 (1) Purdy 2018 (2) Shi 2023 Total (95% C1) Heterogeneity: Tau ² = Test for overall effect: Study or Subgroup Azemati 2005 (1) Chung 2017 (1) Chung 2017 (1) Chung 2017 (2)	Mean 1.6 2.7 2.7 2.3 1.3 2.42 2.12 2.2 2.	SD 0.58 0.58 0.58 1.22 1.22 1.22 0.58 0.58 0.51 1.25 0.66 0.61 0.147 hi ⁰ = 2 0.61 0.14 hi ⁰ = 2 0.14 1.25 0.61 0.14 1.12 1.22 1.22 0.14 1.12 1.25 0.61 0.14 1.12 1.22 1.23 1.24 1.25 0.61 0.14 1.22 1.22 1.22 1.22 1.22 1.22 1.22 1.22 1.22 1.22 1.22 1.22 1.22<	Total 1 22 30 30 30 23 63 30 23 63 30 25 25 25 25 30 16 12 107 543 0.0001 9 Total 2 30 30 30	Mean 3.2 4 5 2.75 4.67 3.2 2.84 2.04 2.04 2.04 2.04 2.04 4 df = 1:) 1.9 1.9 1.9 1.9	SD SD 1.03 1.46 1.96 0.79 0.78 0.68 0.9 0.45 0.98 0.45 0.98 0.45 0.98 0.45 0.99 0.61 5 (P <	Total V 24 24 24 31 30 22 67 30 25 25 30 22 12 12 101 50 50 30 539 1 25 8 30 50 50 30 539 1 6 3 6 2 28 3 6 2	Veight 6.1% - 6.1% - 6.4% - 6.4% - 6.4% - 6.7% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% - 6.5% - 6.1% - - - 0.0% - 1); i' = 93 - 0 6.52 - 6.33 0 6.52 - 6.33 5 6.33 - 6.33	IV, Random, 95% CI 1.86 [-2.56, -1.16] 0.95 [-1.48, -0.42] 1.39 [-1.96, -0.82] 1.39 [-1.96, -0.82] 5.57 [-7.88, -5.25] -0.30 [-0.86, 0.26] -0.36 [-0.64, 0.47] 0.30 [-0.56, 0.26] -0.38 [-0.64, 0.42] 0.30 [-0.51, 0.51] -0.32 [-0.72, 0.07] 2.79 [-3.51, -2.07] -1.02 [-1.51, -0.52] % Std. Mean Different IV, Random, 95 ~0.32 [-0.73, 0.72] .002 [-0.73, 0.73] .003 [-0.27, 0.73, 0.74]	Year 1988 2005 2005 2015 2016 2016 2016 2017 2018 2018 2018 2018 2018 2018 2018 2018	IV, Random, 95% CI
Study or Subgroup Smith 1988 Azemati 2005 (1) Azemati 2005 (2) Kasem 2014 Hamill 2015 Shah 2016 Gupta 2016 (1) Gupta 2016 (2) Chung 2017 (1) Chung 2017 (2) Chung 2017 (2) Chung 2017 (2) Chung 2018 (2) Kinjo 2019 Laguduvah 2022 Shi 2023 Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: : Study or Subgroup Azemati 2005 (1) Azemati 2005 (1) Chung 2017 (1) Chung 2017 (2) Dingerman 2013	Mean 1.6 2.7 2.7 2.3,53 2.75 2.55 2.56 2.22 2.55 2.56 2.55 2	SD 0.58 0.58 0.58 1.22 1.22 1.22 1.22 1.22 0.58 0.50 0.01 1.25 0.66 0.88 1.25 0.61 0.14 hil ² = 2 1.27 1.20 1.27 1.22 1.22 1.25 0.61 0.74	Total 1 22 30 30 30 23 63 30 23 25 25 25 25 30 16 12 25 30 16 12 50 50 50 50 50 50 30 543 007.28, 0.0001 30 543 36 2 30 2 30 543 36 2 30 30 30 30 30 543 30 30 30 30 30 543 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 </td <td>Mean 3.2 4 5 2.75 4.67 3.2 4.67 3.2 3.4 2.04 2 2.04 2 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.5 4 0 1.1 1.9 1.9 1.9 1.9 1.9 2.2</td> <td>SD </td> <td>Total Y 24 24 24 31 30 31 30 22 25 25 20 25 21 101 50 539 539 101 539 101 54 8 6 33 6 2 6 3 8 3 6 2 9 2</td> <td>Veight 6.1% - 6.1% - 6.4% - 6.4% - 6.4% - 6.3% - 6.7% - 4.7% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% 6.4% - - 6.5% 6.0% - - 6.7% - - - 6.7% - - - 6.7% - - - 6.7% - - - 6.7% - - - 0.00.0% - - - 1): 1² 93 - - 4 Weight - - 0 6.55 - - 0 6.55 - - 5 6.33 - - 5 6.33 -</td> <td>VV, Random, 95% CI 1.86 [-2.56, -1.16] 0.95 [-1.48, -0.42] 1.39 [-1.96, -0.82] 1.31 [-1.74, -0.48] 1.48 [-0.64, -0.82] -0.30 [-0.86, 0.26] -0.30 [-0.86, 0.26] -0.30 [-0.86, 0.26] -0.31 [-0.64, 0.67] -0.28 [-0.64, 0.28] 0.11 [-0.44, 0.67] -0.29 [-0.58, 0.55] -0.30 [-0.51, 0.51] -0.32 [-0.72, 0.07] 0.35 [-1.69, -0.01] 0.15 [-0.13, 0.42] -0.32 [-0.72, 0.07] 1.02 [-1.51, -0.52] % -0.27 [-0.73, (-0.27 [-0.73, (% -0.32 [-0.73, (% -0.32 [-0.73, (% -0.32 [-0.73, (% -0.32 [-0.73, (</td> <td>Year 1988 2005 2005 2014 2015 2016 2016 2016 2017 2017 2017 2017 2017 2017 2017 2017</td> <td>IV, Random, 95% CI</td>	Mean 3.2 4 5 2.75 4.67 3.2 4.67 3.2 3.4 2.04 2 2.04 2 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.5 4 0 1.1 1.9 1.9 1.9 1.9 1.9 2.2	SD	Total Y 24 24 24 31 30 31 30 22 25 25 20 25 21 101 50 539 539 101 539 101 54 8 6 33 6 2 6 3 8 3 6 2 9 2	Veight 6.1% - 6.1% - 6.4% - 6.4% - 6.4% - 6.3% - 6.7% - 4.7% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% 6.4% - - 6.5% 6.0% - - 6.7% - - - 6.7% - - - 6.7% - - - 6.7% - - - 6.7% - - - 0.00.0% - - - 1): 1 ² 93 - - 4 Weight - - 0 6.55 - - 0 6.55 - - 5 6.33 - - 5 6.33 -	VV, Random, 95% CI 1.86 [-2.56, -1.16] 0.95 [-1.48, -0.42] 1.39 [-1.96, -0.82] 1.31 [-1.74, -0.48] 1.48 [-0.64, -0.82] -0.30 [-0.86, 0.26] -0.30 [-0.86, 0.26] -0.30 [-0.86, 0.26] -0.31 [-0.64, 0.67] -0.28 [-0.64, 0.28] 0.11 [-0.44, 0.67] -0.29 [-0.58, 0.55] -0.30 [-0.51, 0.51] -0.32 [-0.72, 0.07] 0.35 [-1.69, -0.01] 0.15 [-0.13, 0.42] -0.32 [-0.72, 0.07] 1.02 [-1.51, -0.52] % -0.27 [-0.73, (-0.27 [-0.73, (% -0.32 [-0.73, (% -0.32 [-0.73, (% -0.32 [-0.73, (% -0.32 [-0.73, (Year 1988 2005 2005 2014 2015 2016 2016 2016 2017 2017 2017 2017 2017 2017 2017 2017	IV, Random, 95% CI
Study or Subgroup Smith 1988 Azemati 2005 (1) Azemati 2005 (2) Kasem 2014 Hamill 2015 Shah 2016 Gupta 2016 (2) Chung 2017 (1) Chung 2017 (2) Cho 2018 (2) Kinjo 2019 Laguduyah 2022 Shi 2023 Total (95% CI) Heterogeneity: Tau ² = Test for overall effect : Study or Subgroup Azemati 2005 (1) Chung 2017 (1) Chung 2017 (2) Dingerman 2013 Gupta 2016 (1)	Mean 1.6 2.7 2.7 2.3 3.53 1.2 2.75 2.12 2.2 2.	SD 0.58 0.52 1.22 1.22 1.22 0.53 0.51 1.25 1.25 1.25 0.66 0.88 1.9 0.61 0.14 hi² = 2 1.22 1.22 1.23 1.47 1.61 0.14 hi² = 2 0.122 1.22 1.23 1.24 1.25 0.61 0.14 0.62 1.47 1.41	Total 1 22 30 30 30 23 63 30 23 63 30 25 25 25 25 30 16 12 107 50 543 0.0001 543 0.0001 300 543 300 543 300 543 300 543 300 543 300 543 300 543 300 543 300 543 300 543 300 543 300 543 300 543 300 543 300 543 300 543 300 543 300 544 255 55 24 55 24 55 24 <td>Mean 3.2 4 5 2 75 4.25 4.25 4.25 4.25 3.2 2.2.84 2.04 2 2.04 2 3.4 2.04 2 3.4 2.14 3.2 3.4 4 4 1<</td> <td>SD </td> <td>Total V 24 24 30 31 31 30 22 67 30 25 25 25 25 25 25 25 25 26 12 101 50 539 1 50 0.00000</td> <td>Veight 6.1% - 6.1% - 6.4% - 6.4% - 6.4% - 6.7% - 6.7% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% 6.4% - - 6.4% 6.4% - - 6.1% - - - 6.1% - - - 6.1% - - - 00.0% - - - 1): 1² 93 - - 10 6.5% - - 5 6.3% - - 5 6.3% - -</td> <td>IV, Random, 95% CI 1.86 [-2.56, -1.16] 0.95 [-1.48, -0.42] 1.39 [-1.96, -0.82] 1.39 [-1.96, -0.82] 5.57 [-7.88, -5.25] -0.30 [-0.86, 0.26] -0.36 [-0.64, 0.47] 0.31 [-0.44, 0.67] 0.32 [-0.86, 0.26] -0.32 [-0.84, 0.28] 0.31 [-0.31, 0.42] -0.32 [-0.72, 0.07] 2.79 [-3.51, -2.07] -1.02 [-1.51, -0.52] % 0.02 [-0.73, 6 0.03 [-0.25, 6] 0.04 [-0.51, 0.51] 0.35 [-0.38, 0.22] % 0.02 [-0.72, 0.07] 2.79 [-3.51, -2.07] 1.02 [-1.51, -0.52] % 0.03 [-0.25, 0] % 0.03 [-0.25, 0] % 0.03 [-0.35, 0] 0.03 [-0.35, 0] 0.03 [-0.45, 0] % 0.03 [-0.57, 0] 0.03 [-0.57, 0]</td> <td>Year 1988 2005 2005 2014 2015 2016 2016 2016 2016 2016 2018 2018 2018 2018 2018 2018 2018 2018</td> <td>IV, Random, 95% CI</td>	Mean 3.2 4 5 2 75 4.25 4.25 4.25 4.25 3.2 2.2.84 2.04 2 2.04 2 3.4 2.04 2 3.4 2.14 3.2 3.4 4 4 1<	SD	Total V 24 24 30 31 31 30 22 67 30 25 25 25 25 25 25 25 25 26 12 101 50 539 1 50 0.00000	Veight 6.1% - 6.1% - 6.4% - 6.4% - 6.4% - 6.7% - 6.7% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% 6.4% - - 6.4% 6.4% - - 6.1% - - - 6.1% - - - 6.1% - - - 00.0% - - - 1): 1 ² 93 - - 10 6.5% - - 5 6.3% - - 5 6.3% - -	IV, Random, 95% CI 1.86 [-2.56, -1.16] 0.95 [-1.48, -0.42] 1.39 [-1.96, -0.82] 1.39 [-1.96, -0.82] 5.57 [-7.88, -5.25] -0.30 [-0.86, 0.26] -0.36 [-0.64, 0.47] 0.31 [-0.44, 0.67] 0.32 [-0.86, 0.26] -0.32 [-0.84, 0.28] 0.31 [-0.31, 0.42] -0.32 [-0.72, 0.07] 2.79 [-3.51, -2.07] -1.02 [-1.51, -0.52] % 0.02 [-0.73, 6 0.03 [-0.25, 6] 0.04 [-0.51, 0.51] 0.35 [-0.38, 0.22] % 0.02 [-0.72, 0.07] 2.79 [-3.51, -2.07] 1.02 [-1.51, -0.52] % 0.03 [-0.25, 0] % 0.03 [-0.25, 0] % 0.03 [-0.35, 0] 0.03 [-0.35, 0] 0.03 [-0.45, 0] % 0.03 [-0.57, 0] 0.03 [-0.57, 0]	Year 1988 2005 2005 2014 2015 2016 2016 2016 2016 2016 2018 2018 2018 2018 2018 2018 2018 2018	IV, Random, 95% CI
Study or Subgroup Smith 1988 Azemati 2005 (1) Azemati 2005 (2) Kasem 2014 Hamill 2015 Shah 2016 Gupta 2016 (1) Gupta 2016 (2) Chung 2017 (2) Chung 2017 (2) Chung 2017 (2) Chung 2017 (2) Chung 2018 (2) Kinjo 2019 Lagoduvah 2022 Shi 2023 Total (95% CI) Heterogeneity: Tau ² = Test for overall effect : Study or Subgroup Azemati 2005 (1) Azemati 2005 (2) Chung 2017 (1) Chung 2017 (2) Dingerman 2013 Gupta 2016 (2)	Mean 1.6 2.7 2.77 2.75 2.54 2.75 2.54 2.75 2.54 2.54 2.54 2.55 2.	SD 0.58 0.58 1.22 1.22 1.22 1.22 0.58 0.50 0.51 1.25 0.66 0.88 1.9 0.61 0.14 hi ⁰ = 2 1.25 0.09 1.25 1.09 1.23 1.47 1.61 0.14 hi ⁰ = 2 1.25 1.25 1.25 0.238 1.47 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 </td <td>Total 1 22 30 30 30 23 63 30 23 63 30 25 25 25 25 25 25 25 25 25 25 25 25 30 16 12 30 543 30 0.0001 007.28 30 30 543 30 0.0001 007.28 30 30 543 30 255 30 300 30 543 30 30 30 25 30 300 30 543 30 30 30 30 30 30 30 30 30 30 30 30 30</td> <td>Mean 3.2 4 5 2.75 4.25 4.25 4.25 4.25 4.25 2.84 2.04 2 2.84 2.04 2 3.4 2.14 3.25 4.47 1.4 2.14 3.25 4.47 1.4 2.04 4.5 1.2 2.04 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.</td> <td>SD 1.03 1.46 1.96 0.79 0.47 0.78 0.47 0.9 0.45 0.98 2.4 2.4 2.4 2.4 2.4 3.14 3.14 3.09 2.0.8 9.2 0.8 2.0.8 9.15.5 6.1.1</td> <td>Total V 24 24 30 31 31 30 22 25 25 25 25 26 25 30 12 121 101 539 1 530 0.00000 6 38 8 3 6 2 9 2 3 2 2 2</td> <td>Veight 6.1% - 6.1% - 6.4% - 6.4% - 6.4% - 6.7% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% 6.4% - - 6.7% - - - 6.7% - - - 6.7% - - - 6.7% - - - 6.7% - - - 6.7% - - - 6.7% - - - 93 - - - - 0 - - - - 0 - - - - 0 - - - - 0 - - - - <!--</td--><td>VV. Random, 95% CI 1.36 [-2.56, -1.16] 0.95 [-1.48, -0.42] 1.39 [-1.96, -0.82] 1.39 [-1.96, -0.82] 1.39 [-1.96, -0.82] 0.57 [-7.88, -5.25] -0.30 [-0.86, 0.26] -0.38 [-0.64, 0.47] 0.30 [-0.54, 0.28] 0.11 [-0.44, 0.67] 0.20 [-0.55, 0.55] 0.35 [-0.13, 0.42] -0.32 [-0.72, 0.07] 2.79 [-3.51, -2.07] 1.02 [-1.51, -0.52] % -0.27 [-0.73, 0 % -0.27 [-0.73, 0 % -0.27 [-0.73, 0 % -0.27 [-0.73, 0 % -0.32 [-0.75, 0 % -0.32 [-0.73, 0 % -0.32 [-0.73, 0 % -0.32 [-0.73, 0 % -0.32 [-0.73, 0 % -0.32 [-0.73, 0 % -0.32 [-0.73, 0 % -0.32 [-0.73, 0 % -0.32 [-0.73, 0 % -0.32 [-0.73, 0 % -0.32 [-0.73, 0 % -0.32 [-0.73, 0 % -0.32 [-0.73, 0 % -0.32 [-0.73, 0 % -0.32 [-0.73, 0 % -0.33 [-0.45, 0 % -0.33 [-0.45,</td><td>Year 1988 2005 2005 2005 2014 2015 2016 2016 2016 2016 2016 2017 2017 2017 2017 2017 2017 2017 2017</td><td>IV, Random, 95% CI</td></td>	Total 1 22 30 30 30 23 63 30 23 63 30 25 25 25 25 25 25 25 25 25 25 25 25 30 16 12 30 543 30 0.0001 007.28 30 30 543 30 0.0001 007.28 30 30 543 30 255 30 300 30 543 30 30 30 25 30 300 30 543 30 30 30 30 30 30 30 30 30 30 30 30 30	Mean 3.2 4 5 2.75 4.25 4.25 4.25 4.25 4.25 2.84 2.04 2 2.84 2.04 2 3.4 2.14 3.25 4.47 1.4 2.14 3.25 4.47 1.4 2.04 4.5 1.2 2.04 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.	SD 1.03 1.46 1.96 0.79 0.47 0.78 0.47 0.9 0.45 0.98 2.4 2.4 2.4 2.4 2.4 3.14 3.14 3.09 2.0.8 9.2 0.8 2.0.8 9.15.5 6.1.1	Total V 24 24 30 31 31 30 22 25 25 25 25 26 25 30 12 121 101 539 1 530 0.00000 6 38 8 3 6 2 9 2 3 2 2 2	Veight 6.1% - 6.1% - 6.4% - 6.4% - 6.4% - 6.7% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% 6.4% - - 6.7% - - - 6.7% - - - 6.7% - - - 6.7% - - - 6.7% - - - 6.7% - - - 6.7% - - - 93 - - - - 0 - - - - 0 - - - - 0 - - - - 0 - - - - </td <td>VV. Random, 95% CI 1.36 [-2.56, -1.16] 0.95 [-1.48, -0.42] 1.39 [-1.96, -0.82] 1.39 [-1.96, -0.82] 1.39 [-1.96, -0.82] 0.57 [-7.88, -5.25] -0.30 [-0.86, 0.26] -0.38 [-0.64, 0.47] 0.30 [-0.54, 0.28] 0.11 [-0.44, 0.67] 0.20 [-0.55, 0.55] 0.35 [-0.13, 0.42] -0.32 [-0.72, 0.07] 2.79 [-3.51, -2.07] 1.02 [-1.51, -0.52] % -0.27 [-0.73, 0 % -0.27 [-0.73, 0 % -0.27 [-0.73, 0 % -0.27 [-0.73, 0 % -0.32 [-0.75, 0 % -0.32 [-0.73, 0 % -0.32 [-0.73, 0 % -0.32 [-0.73, 0 % -0.32 [-0.73, 0 % -0.32 [-0.73, 0 % -0.32 [-0.73, 0 % -0.32 [-0.73, 0 % -0.32 [-0.73, 0 % -0.32 [-0.73, 0 % -0.32 [-0.73, 0 % -0.32 [-0.73, 0 % -0.32 [-0.73, 0 % -0.32 [-0.73, 0 % -0.32 [-0.73, 0 % -0.33 [-0.45, 0 % -0.33 [-0.45,</td> <td>Year 1988 2005 2005 2005 2014 2015 2016 2016 2016 2016 2016 2017 2017 2017 2017 2017 2017 2017 2017</td> <td>IV, Random, 95% CI</td>	VV. Random, 95% CI 1.36 [-2.56, -1.16] 0.95 [-1.48, -0.42] 1.39 [-1.96, -0.82] 1.39 [-1.96, -0.82] 1.39 [-1.96, -0.82] 0.57 [-7.88, -5.25] -0.30 [-0.86, 0.26] -0.38 [-0.64, 0.47] 0.30 [-0.54, 0.28] 0.11 [-0.44, 0.67] 0.20 [-0.55, 0.55] 0.35 [-0.13, 0.42] -0.32 [-0.72, 0.07] 2.79 [-3.51, -2.07] 1.02 [-1.51, -0.52] % -0.27 [-0.73, 0 % -0.27 [-0.73, 0 % -0.27 [-0.73, 0 % -0.27 [-0.73, 0 % -0.32 [-0.75, 0 % -0.32 [-0.73, 0 % -0.32 [-0.73, 0 % -0.32 [-0.73, 0 % -0.32 [-0.73, 0 % -0.32 [-0.73, 0 % -0.32 [-0.73, 0 % -0.32 [-0.73, 0 % -0.32 [-0.73, 0 % -0.32 [-0.73, 0 % -0.32 [-0.73, 0 % -0.32 [-0.73, 0 % -0.32 [-0.73, 0 % -0.32 [-0.73, 0 % -0.32 [-0.73, 0 % -0.33 [-0.45, 0 % -0.33 [-0.45,	Year 1988 2005 2005 2005 2014 2015 2016 2016 2016 2016 2016 2017 2017 2017 2017 2017 2017 2017 2017	IV, Random, 95% CI
Study or Subgroup Study or Subgroup Azemati 2005 (1) Azemati 2005 (2) Kasem 2014 Hamill 2015 Shah 2016 (1) Gupta 2016 (2) Chung 2017 (1) Chung 2017 (2) Cho 2018 (2) Purdy 2018 (2) Kinjo 2019 Purdy 2018 (2) Kinjo 2019 Cotal (95% C) Heterogeneity: Tau ² = Test for overall effect : Study or Subgroup Azemati 2005 (1) Azemati 2005 (2) Chung 2017 (1) Chung 2017 (2) Dingerman 2013 Cupta 2016 (2) How 2015 (2) Subgroup 5 Subgroup 5 Subgroup 2015 (2) Subgroup 2015	Mean 1.6 2.7 2.7 2.75 2.7	SD SD 0.58 0.58 1.22 0.52 0.50 0.51 1.25 0.52 1.25 0.66 1.25 1.25 1.25 0.66 1.47 1.6 0.61 0.14 hil ² = 2 0.0 (P <	Total 22 22 30 30 30 23 30 30 23 23 30 23 23 30 23 23 30 23 23 30 23 23 25 25 25 25 25 25 25 25 25 30 107 50 30 563 30 563 30 563 30 25 25 26 30 30 30 563 30 20 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30 30	Mean 3.2 4 5 2.75 4.25 4.25 4.25 4.25 4.25 2.84 2.04 2.04 2.04 2.04 2.04 4.21 4 4 4 1.1 1.1 1.2 1.2 3.7 3.2 3.3 3.3 3.3 3.3 3.3 3.3 3.3	SD	Total V 24 244 30 31 31 30 22 67 30 25 25 25 25 25 25 25 25 26 12 101 50 539 101 50 0.00000 66 33 88 33 88 3 26 2 29 2 22 2 22 2 23 2 24 2 25 3 26 6 27 2 28 3 29 2 20 2 20 2 20 2 30 3	Veight 6.1% - 6.1% - 6.4% - 6.4% - 6.4% - 6.3% - 6.7% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% 6.4% - - 6.1% - - - 6.1% - - - 6.1% - - - 0.0.0% - - - 0 6.51 - - 0 6.52 - - 11 Weight - - 0 6.53 - - 5 6.33 - - 5 6.33 - - 5 6.33 - - 5 6.33 - - 5 6.33 -	VV. Random, 95% C1 1.86 [-2.56, -1.16] 0.95 [-1.48, -0.42] 1.39 [-1.96, -0.82] 1.39 [-1.96, -0.82] -0.30 [-0.86, 0.26] -0.30 [-0.86, 0.26] -0.30 [-0.86, 0.26] -0.30 [-0.86, 0.26] -0.28 [-0.84, 0.28] 0.11 [-0.44, 0.67] 0.00 [-0.51, 0.51] -0.20 [-0.95, 0.55] 0.35 [-1.69, -0.07] 2.79 [-3.51, -2.07] -1.02 [-1.51, -0.52] % Std. Mean Different IV. Random, 99 % -0.22 [-0.72, 0.07] 5% 5td. Mean Different IV. Random, 99 % -0.22 [-0.73, 0 % 0.13 [-0.87, 0 % 0.13 [-0.45, 0 % 0.13 [-0.45, 0 % 0.13 [-0.45, 0 % 0.11 [-0.45, 0 % 0.11 [-0.45, 0 % 0.11 [-0.57, 0	Year 1988 2005 2005 2005 2016 2016 2016 2016 2016 2018 2018 2018 2018 2018 2018 2018 2018	IV, Random, 95% CI
Study or Subgroup Study or Subgroup Azemati 2005 (1) Azemati 2005 (2) Kasem 2014 Hamill 2015 Shah 2016 Gupta 2016 (1) Gupta 2016 (2) Chung 2017 (1) Chung 2017 (2) Cho 2018 Purdy 2018 (2) Kinjo 2019 Lagoduvah 2022 Shi 2023 Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: Dingerman 2013 Cupta 2016 (2) Dingerman 2013 Cupta 2016 (2) Hamill 2015 Kinjo 2019	$\begin{array}{c} \textbf{Mean} \\ 1.6 \\ 2.7 \\ 2.7 \\ 2.3 \\ 5.3 \\ 1 \\ 2.75 \\ 2.75 \\ 2.75 \\ 2.75 \\ 2.2 \\ 2 \\ 2 \\ 3 \\ 3.2 \\ 2.12 \\ 2 \\ 3 \\ 2.75 \\ 0.92 \\ C \\ 2 \\ 2 \\ 4.0 \\ 0.92 \\ C \\ 2 \\ 2 \\ 3 \\ 3.7 \\ 3.4 \\ 3.4 \\ 3.7 \\ 3.4 \\ 3.7 \\ 3.4 \\ 3.4 \\ 3.7 \\ 3.4 \\ 3.4 \\ 3.7 \\ 3.4 \\ 3$	SD 0.58 0.58 1.22 1.22 0.52 0.51 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 0.61 0.14 hd² = 2 0.99 1.25 1.23 1.24 1.25 1.26 0.61 0.14 hd² = 2 0.99 1.22 1.91 1.02 1.03 1.04 1.04 1.04 1.04 1.04 1.05	Total 1 22 30 30 30 23 63 30 23 63 30 25 25 25 25 25 25 25 25 25 25 25 25 30 16 12 50 50 30 50 50 50 30 63 30 0.00001 543 0.00001 30 0 300 2 25 2 30 30 30 30 30 2 30 2 25 30 30 2 25 30 30 2 25 30 30 2 25 30 30 2	Mean 3.2 4 5 2.75 4.25 2.75 4.25 4.25 4.25 2.84 2.04 2 2.84 2.04 2 2.84 4 2.04 4 2 3.4 2.04 4 1.2 3.4 2.04 4 1.2 2.04 4 2.04 2.04 4 2.04 4 2.04 1.2 2.04 4 2.04 1.2 3.2 2.15 1.2 2.0 1.1 1.1 1.2 3.2 3.7 3.2 3.2 3.4 3.2 3.2 3.2 3.4 3.2 3.2 3.2 3.4 3.2 3.2 3.2 3.4 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2	SD SD 1.03 1.46 1.96 0.79 0.79 0.47 0.70 0.78 0.90 0.45 0.93 0.44 0.90 0.45 5 (P <	Total V 24 244 24 24 30 31 30 32 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 30 12 12 12 101 530 530 10 530 10 538 33 6 2 9 2 2 2 6 2 2 2 6 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 3 2 3 2 3 2 3 2 <td< td=""><td>Veight 6.1% - $6.1%$ - 6.4% - 6.4% - 6.7% - 6.7% - 6.4% - 6.4% - - - 6.7% - - - 0.0% - - - $0.6.5\%$ - - - $0.6.5\%$ - - - $0.6.5\%$ - - - <</td><td>VV. Random, 95% C1 1.86 [-2.56, -1.16] 0.95 [-1.48, -0.42] 1.39 [-1.96, -0.82] 1.39 [-1.96, -0.82] 1.39 [-1.96, -0.82] 0.57 [-7.88, -5.25] -0.30 [-0.86, 0.26] -0.08 [-0.64, 0.47] 0.00 [-0.51, 0.51] -0.28 [-0.48, 0.28] 0.11 [-0.44, 0.67] 0.00 [-0.51, 0.51] -0.28 [-0.48, 0.28] 0.15 [-0.13, 0.42] -0.32 [-0.72, 0.07] 2.79 [-3.51, -2.07] 1.02 [-1.51, -0.52] % 5 5 5 5 5 5 5 5 5 5 5 5 5</td><td>Year 1988 2005 2005 2014 2015 2016 2016 2016 2016 2016 2016 2016 2017 2018 2018 2019 2022 2023 2023 2023 2022 2023 2023 202</td><td>IV, Random, 95% CI</td></td<>	Veight 6.1% - $6.1%$ - 6.4% - 6.4% - 6.7% - 6.7% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% - - - 6.4% - - - 6.4% - - - 6.4% - - - 6.4% - - - 6.4% - - - 6.4% - - - 6.7% - - - 0.0% - - - $0.6.5\%$ - - - $0.6.5\%$ - - - $0.6.5\%$ - - - <	VV. Random, 95% C1 1.86 [-2.56, -1.16] 0.95 [-1.48, -0.42] 1.39 [-1.96, -0.82] 1.39 [-1.96, -0.82] 1.39 [-1.96, -0.82] 0.57 [-7.88, -5.25] -0.30 [-0.86, 0.26] -0.08 [-0.64, 0.47] 0.00 [-0.51, 0.51] -0.28 [-0.48, 0.28] 0.11 [-0.44, 0.67] 0.00 [-0.51, 0.51] -0.28 [-0.48, 0.28] 0.15 [-0.13, 0.42] -0.32 [-0.72, 0.07] 2.79 [-3.51, -2.07] 1.02 [-1.51, -0.52] % 5 5 5 5 5 5 5 5 5 5 5 5 5	Year 1988 2005 2005 2014 2015 2016 2016 2016 2016 2016 2016 2016 2017 2018 2018 2019 2022 2023 2023 2023 2022 2023 2023 202	IV, Random, 95% CI
Study or Subgroup Azemati 2005 (1) Azemati 2005 (2) Azemati 2005 (2) Azemati 2005 (2) Kasem 2014 Hamill 2015 Shah 2016 (2) Chung 2017 (1) Chung 2017 (2) Cho 2018 (2) Purdy 2018 (2) Kinjo 2019 Laguduvah 2022 Study or Subgroup Azemati 2005 (1) Azemati 2005 (1) Azemati 2005 (2) Chung 2017 (1) Chung 2017 (1) Chung 2017 (2) Dingerman 2013 Gupta 2016 (1) Gupta 2016 (2) Hamill 2015 Kinjo 2019 Laguduvah 2022	Mean 1.6 2.7 2.7 2.75 2.7	SD 0.58 0.58 0.52 0.52 0.52 0.52 0.52 0.52 0.52 0.52 0.52 0.52 0.52 0.52 0.63 1.25 1.25 0.61 1.47 1.62 1.223 0.61 hh ² = 2 0.14 1.22 1.23 0.64 SC 1.23 0.64 SC 1.22 1.23 0.64 SC 1.22 1.23 0.64 2.05 1.41 1.42 1.07 1.23 0.33 1.24 1.24 1.24 1.24 1.25 </td <td>Total 2 22 30 30 30 23 30 23 23 23 23 23 25 25 25 25 25 25 25 25 25 25</td> <td>Mean 3.2 4 5 2.75 4.25 4.25 4.25 4.25 2.84 2.04 2.04 2.04 2.04 2.04 2.04 4.3.4 4 4 df = 1:) 1.9 1.9 2.2 3.7 3.7 3.7 3.7 3.7 3.7 3.7 3.7</td> <td>SD 1.03 1.46 1.96 0.79 0.47 0.79 0.47 0.79 0.45 0.98 2.4 1.9 0.9 0.45 0.9 0.45 0.9 0.61 5 0.9 0.61 3 1.43 0.9 2 0.8 2 0.61 1.9 0.61 1.9 0.9 0.61 1.9 0.9 1.1 0.9 1.1 1.0 0.1 1.1 1.0 0.11 1.0 0.11 1.0 0.11</td> <td>Total Y 24 24 24 30 31 30 30 22 67 30 25 25 25 25 25 25 101 50 539 101 50 700000 66 30 88 30 66 2 30 22 31 101 50 539 66 2 30 2 30 2 23 2 32 2 33 2 2 2 33 2 33 2 33 2 33 2 34 2 35 3 36 6 37 2 38 3 30 2<td>Veight 6.1% - 6.1% - 6.4% - 6.4% - 6.4% - 6.3% - 6.7% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% 6.4% - - 6.5% 6.0% - - 6.1% 6.7% - - 6.1% - 00.0% - 11; 1² 93 - - 12; 1² - 03.55 - - 13; 5 6.33 - - - 14 Weight - - - - 15 6.33 - - - - 15 6.33 - - - - 16 115 5 6.33 - - 15 6.33</td><td>VV, Random, 95% C1 1.86 [-2.56, -1.16] 0.95 [-1.48, -0.42] 1.39 [-1.96, -0.82] 1.39 [-1.96, -0.82] -0.30 [-0.86, 0.26] -0.30 [-0.86, 0.26] -0.30 [-0.86, 0.26] -0.30 [-0.84, 0.28] 0.11 [-0.44, 0.67] 0.00 [-0.51, 0.51] -0.20 [-0.95, 0.55] 0.35 [-1.59, -0.01] 0.35 [-1.59, -0.01] 0.35 [-1.51, -0.52] % Std. Mean Different t. VV, Random, 95 w -0.22 [-0.72, 0.07] % Std. Mean Different t. VV, Random, 95 w -0.22 [-0.73, 0 w -0.32 [-0.87, 0 w -0.31 [-0.45, 0 w -0.31 [-0.45, 0 w -0.11 [-0.45, 0 w -0.11 [-0.45, 0 w -0.13 [-0.14, 0] w -0.14 [-0</td><td>Year 1988 2005 2005 2005 2014 2016 2016 2016 2016 2016 2016 2016 2018 2018 2018 2018 2018 2018 2018 2018</td><td>IV, Random, 95% CI</td></td>	Total 2 22 30 30 30 23 30 23 23 23 23 23 25 25 25 25 25 25 25 25 25 25	Mean 3.2 4 5 2.75 4.25 4.25 4.25 4.25 2.84 2.04 2.04 2.04 2.04 2.04 2.04 4.3.4 4 4 df = 1:) 1.9 1.9 2.2 3.7 3.7 3.7 3.7 3.7 3.7 3.7 3.7	SD 1.03 1.46 1.96 0.79 0.47 0.79 0.47 0.79 0.45 0.98 2.4 1.9 0.9 0.45 0.9 0.45 0.9 0.61 5 0.9 0.61 3 1.43 0.9 2 0.8 2 0.61 1.9 0.61 1.9 0.9 0.61 1.9 0.9 1.1 0.9 1.1 1.0 0.1 1.1 1.0 0.11 1.0 0.11 1.0 0.11	Total Y 24 24 24 30 31 30 30 22 67 30 25 25 25 25 25 25 101 50 539 101 50 700000 66 30 88 30 66 2 30 22 31 101 50 539 66 2 30 2 30 2 23 2 32 2 33 2 2 2 33 2 33 2 33 2 33 2 34 2 35 3 36 6 37 2 38 3 30 2 <td>Veight 6.1% - 6.1% - 6.4% - 6.4% - 6.4% - 6.3% - 6.7% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% 6.4% - - 6.5% 6.0% - - 6.1% 6.7% - - 6.1% - 00.0% - 11; 1² 93 - - 12; 1² - 03.55 - - 13; 5 6.33 - - - 14 Weight - - - - 15 6.33 - - - - 15 6.33 - - - - 16 115 5 6.33 - - 15 6.33</td> <td>VV, Random, 95% C1 1.86 [-2.56, -1.16] 0.95 [-1.48, -0.42] 1.39 [-1.96, -0.82] 1.39 [-1.96, -0.82] -0.30 [-0.86, 0.26] -0.30 [-0.86, 0.26] -0.30 [-0.86, 0.26] -0.30 [-0.84, 0.28] 0.11 [-0.44, 0.67] 0.00 [-0.51, 0.51] -0.20 [-0.95, 0.55] 0.35 [-1.59, -0.01] 0.35 [-1.59, -0.01] 0.35 [-1.51, -0.52] % Std. Mean Different t. VV, Random, 95 w -0.22 [-0.72, 0.07] % Std. Mean Different t. VV, Random, 95 w -0.22 [-0.73, 0 w -0.32 [-0.87, 0 w -0.31 [-0.45, 0 w -0.31 [-0.45, 0 w -0.11 [-0.45, 0 w -0.11 [-0.45, 0 w -0.13 [-0.14, 0] w -0.14 [-0</td> <td>Year 1988 2005 2005 2005 2014 2016 2016 2016 2016 2016 2016 2016 2018 2018 2018 2018 2018 2018 2018 2018</td> <td>IV, Random, 95% CI</td>	Veight 6.1% - 6.1% - 6.4% - 6.4% - 6.4% - 6.3% - 6.7% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% 6.4% - - 6.5% 6.0% - - 6.1% 6.7% - - 6.1% - 00.0% - 11; 1² 93 - - 12; 1² - 03.55 - - 13; 5 6.33 - - - 14 Weight - - - - 15 6.33 - - - - 15 6.33 - - - - 16 115 5 6.33 - - 15 6.33	VV, Random, 95% C1 1.86 [-2.56, -1.16] 0.95 [-1.48, -0.42] 1.39 [-1.96, -0.82] 1.39 [-1.96, -0.82] -0.30 [-0.86, 0.26] -0.30 [-0.86, 0.26] -0.30 [-0.86, 0.26] -0.30 [-0.84, 0.28] 0.11 [-0.44, 0.67] 0.00 [-0.51, 0.51] -0.20 [-0.95, 0.55] 0.35 [-1.59, -0.01] 0.35 [-1.59, -0.01] 0.35 [-1.51, -0.52] % Std. Mean Different t. VV, Random, 95 w -0.22 [-0.72, 0.07] % Std. Mean Different t. VV, Random, 95 w -0.22 [-0.73, 0 w -0.32 [-0.87, 0 w -0.31 [-0.45, 0 w -0.31 [-0.45, 0 w -0.11 [-0.45, 0 w -0.11 [-0.45, 0 w -0.13 [-0.14, 0] w -0.14 [-0	Year 1988 2005 2005 2005 2014 2016 2016 2016 2016 2016 2016 2016 2018 2018 2018 2018 2018 2018 2018 2018	IV, Random, 95% CI
Study or Subgroup Smith 1988 Azemati 2005 (1) Azemati 2005 (2) Kasem 2014 Hamill 2015 Shah 2016 Gupta 2016 (1) Gupta 2016 (2) Chung 2017 (2) Chung 2017 (2) Chung 2017 (2) Chung 2017 (2) Chung 2017 (2) Chung 2017 (2) Chung 2018 (2) Kinjo 2019 Laguduvah 2022 Shi 2023 Total (95% CI) Heterogeneity: Tau ² = Test for overall effect : Study or Subgroup Azemati 2005 (1) Azemati 2015 (1) Chung 2017 (2) Dingerman 2013 Cupta 2016 (2) Hamill 2015 Kinjo 2019 Laguduvah 2022	$\begin{array}{c} \text{Mean} \\ 1.6 \\ 2.7 \\ 2.7 \\ 2.7 \\ 2.7 \\ 2.7 \\ 2.7 \\ 2.7 \\ 2.7 \\ 2.7 \\ 2.7 \\ 2.7 \\ 2.7 \\ 3.2 \\ 2.7 \\ 3.2 \\ 2.7 \\ 3$	SD 0.58 0.58 0.52 1.22 1.22 0.52 0.51 1.25 1.25 1.25 1.25 1.25 1.25 1.25 0.61 0.61 0.61 0.61 0.62 1.25 1.25 1.23 1.47 1.25 1.23 0.62 0.61 0.61 0.61 0.62 1.22 0.20 1.22 0.20 1.41 1.41 1.52 0.33 1.25 0.34	Total 1 22 30 30 30 30 23 63 30 23 63 30 25 25 25 25 25 25 25 25 25 30 16 12 107 50 30 50 50 50 50 50 30 0.0001 007.28, 30 2 30 30 30 0.0001 007.28, 30 2 30 30 30 2 25 2 24 2 25 2 25 2 25 2 25 2 25 2 25 2 25 30 30 30 30 3	Mean 3.2 4 5 2.75 4.25 4.67 3.2 2.84 4.67 3.2 2.84 4.25 4.25 4.25 4.25 4.25 4.25 2.84 4.25 4.25 2.84 4.25 4.25 2.14 3.2 2.14 3.2 2.14 3.2 2.14 3.2 2.14 3.2 3.4 3.2 3.4 3.2 3.4 3.2 3.4 3.2 3.4 3.2 3.4 3.2 3.4 3.2 3.4 3.2 3.4 3.2 3.4 3.2 3.4 3.4 3.5 3.7 3.7 3.7 3.7 3.7 3.7 3.7 3.7	SD SD 1.03 1.46 1.96 0.79 0.47 0.78 0.47 0.78 0.47 0.78 0.45 0.94 0.45 0.98 2.4 1.90 2.4 1.9 5 (P <	Total V 24 244 24 24 31 30 31 30 22 67 30 25 25 25 25 25 25 25 25 30 12 12 121 50 30 539 1 50 30 530 10 50 30 66 31 88 31 66 2 9 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 3 3 3 3 3 3 3 3 3 3	Veight 6.1% - 6.1% - 6.4% - 6.4% - 6.4% - 6.3% - 6.7% - 6.4% 6.4% 6.4% - 6.4% 6.4% 6.4% - 6.4% 6.4% 6.4% - 6.7% 6.1% - - 6.1% - - - 00.0% - 1); $l^2 = 93$ - 0 6.55 6.33 - 5 6.33 - 6.25 0 6.55 6.33 - 5 6.33 - - 6.35 6.33 - - 7 7.21 1 - 7.22 1 7.02 - - -	IV, Random, 95% CI 1.86 [-2.56, -1.16] 0.95 [-1.48, -0.42] 1.39 [-1.96, -0.82] 1.39 [-1.96, -0.82] 1.31 [-1.74, -0.48] 1.48 [-0.64, -0.82] 0.57 [-7.88, -5.25] -0.30 [-0.66, 0.26] -0.38 [-0.64, 0.28] 0.11 [-0.44, 0.67] 0.00 [-0.51, 0.42] -0.22 [-0.72, 0.07] 2.79 [-3.51, -2.07] 1.02 [-1.51, -0.52] % 0.01 [-0.25, 0.31] 0.00 [-0.51, 0.42] % 0.00 [-0.51, 0.42] 0.32 [-0.72, 0.07] 2.79 [-3.51, -2.07] 1.02 [-1.51, -0.52] % 0.00 [-0.51, 0.42] 0.31 [-0.45, 0.42] 0.32 [-0.73, 0.42] 0.31 [-0.45, 0.42] % 0.03 [-0.51, 0.42] % 0.31 [-0.45, 0.42] % 0.31 [-0.45, 0.42] % 0.31 [-0.45, 0.42] % 0.31 [-0.45, 0.42] % 0.31 [-0.45, 0.42] % 0.31 [-0.45, 0.42] <td>Year 1988 2005 2005 2014 2015 2016 2016 2016 2016 2016 2016 2016 2017 2018 2012 2013 2012 2013 2012 2013 2012 2013 2013</td> <td>IV, Random, 95% CI</td>	Year 1988 2005 2005 2014 2015 2016 2016 2016 2016 2016 2016 2016 2017 2018 2012 2013 2012 2013 2012 2013 2012 2013 2013	IV, Random, 95% CI
Study or Subgroup Smith 1988 Azemati 2005 (1) Azemati 2005 (2) Kasem 2014 Hamill 2015 Shah 2016 (1) Gupta 2016 (2) Chung 2017 (1) Chung 2017 (2) Cho 2018 (2) Wing 2018 (2) Kinjo 2019 Lagudwah 2022 Study or Subgroup Azemati 2005 (1) Azemati 2005 (1) Azemati 2005 (2) Cho 2018 Chung 2017 (1) Chung 2017 (1) Chung 2017 (2) Dingerman 2013 Gupta 2016 (1) Gupta 2016 (2) Hamill 2015 Kinjo 2019 Lagudwah 2022 Myazaki 2017	Mean 1.6 2.7 2.7 2.75 2.7	$\frac{SD}{0.58}$ 1.22 1.22 0.5 0.01 1.22 0.5 0.01 1.25 1.25 0.66 0.88 1.47 1.9 0.64 0.64 0.64 0.64 0.64 0.64 0.64 0.64	Total 22 22 30 30 30 23 30 30 23 63 30 23 23 63 30 25 25 25 25 25 25 25 25 30 16 107 50 30 543 007.28, 30 007.28, 30 007.28, 30 007.28, 30 007.28, 30 007.28, 30 007.28, 30 007.28, 30 007.28, 30 25 20 30 30 25 25 26 27 27 63 28 107 30 30 20 25 21 25 22 25 <td>Mean 3.2 4 5 5 2.75 4.25 4.25 4.25 4.25 2.84 2.04 2.04 2.04 2.04 2.04 2.04 2.04 2.04 2.14 3.4 4 4 4 1.9 1.9 2.15 3.7 3.2 3.2 3.4 3.4 2.04 2.1</td> <td>SD 1.03 1.46 1.96 0.79 1.68 0.78 1.68 0.93 0.45 0.61 5 0.7 0.8 0.9 0.5 0.61 1.1 1.0 0.6 1.1 1.0 0.6 1.1</td> <td>Total Y 24 24 24 30 24 31 30 31 31 30 67 30 22 25 25 25 25 25 25 25 30 12 12 101 50 539 0.00000 0 58 0 0.00000 0 58 33 6 3 6 6 2 2 2 2 2 2 3 2 2 2 2 2 2 2 2 2 2 2 2 2 3 2 2 2 3 2 3 2 3 2</td> <td>Veight 6.1% - 6.1% - 6.4% - 6.4% - 6.4% - 6.3% - 6.7% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% 6.4% - - 6.5% 6.0% - - 6.1% - - - 6.1% - - - 6.1% - - - 0.00.0% - - - 0.1 - - - 0.2 - - - 1 - - - - 5 6.33 - - - 5 6.33 - - - 1 - 1 - - 0 - - - -<!--</td--><td>VV. Random, 95% C1 1.86 [-2.56, -1.16] 0.95 [-1.48, -0.42] 1.39 [-1.96, -0.82] 1.39 [-1.96, -0.82] 1.39 [-1.96, -0.82] 0.30 [-0.86, 0.26] -0.08 [-0.84, 0.28] 0.10 [-0.51, 0.51] -0.28 [-0.84, 0.28] 0.11 [-0.44, 0.67] 0.00 [-0.51, 0.51] -0.20 [-0.95, 0.55] 1.02 [-1.51, -0.01] 0.15 [-0.13, 0.42] -0.32 [-0.72, 0.07] 2.79 [-3.51, -2.07] 1.02 [-1.51, -0.52] % 5td. Mean Different t. VV. Random, 99 -0.22 [-0.73, 0 % -0.27 [-0.78, 0 % -0.31 [-0.24, 0 % -0.11 [-0.45, 0 % -0.11 [-0.57, 0] [-0.57, 0</td><td>Year 1988 2005 2005 2005 2016 2016 2016 2016 2016 2016 2017 2017 2017 2017 2017 2018 2018 2018 2018 2018 2018 2018 2018 2019 2022 2023 2023 2024 2024 2025 2025 2025 2014 2016 2017 2017 2017 2018 2023 2022 2023 2022 2023 2022 2023 2024 2025 2055</td><td>IV, Random, 95% CI</td></td>	Mean 3.2 4 5 5 2.75 4.25 4.25 4.25 4.25 2.84 2.04 2.04 2.04 2.04 2.04 2.04 2.04 2.04 2.14 3.4 4 4 4 1.9 1.9 2.15 3.7 3.2 3.2 3.4 3.4 2.04 2.1	SD 1.03 1.46 1.96 0.79 1.68 0.78 1.68 0.93 0.45 0.61 5 0.7 0.8 0.9 0.5 0.61 1.1 1.0 0.6 1.1 1.0 0.6 1.1	Total Y 24 24 24 30 24 31 30 31 31 30 67 30 22 25 25 25 25 25 25 25 30 12 12 101 50 539 0.00000 0 58 0 0.00000 0 58 33 6 3 6 6 2 2 2 2 2 2 3 2 2 2 2 2 2 2 2 2 2 2 2 2 3 2 2 2 3 2 3 2 3 2	Veight 6.1% - 6.1% - 6.4% - 6.4% - 6.4% - 6.3% - 6.7% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% 6.4% - - 6.5% 6.0% - - 6.1% - - - 6.1% - - - 6.1% - - - 0.00.0% - - - 0.1 - - - 0.2 - - - 1 - - - - 5 6.33 - - - 5 6.33 - - - 1 - 1 - - 0 - - - - </td <td>VV. Random, 95% C1 1.86 [-2.56, -1.16] 0.95 [-1.48, -0.42] 1.39 [-1.96, -0.82] 1.39 [-1.96, -0.82] 1.39 [-1.96, -0.82] 0.30 [-0.86, 0.26] -0.08 [-0.84, 0.28] 0.10 [-0.51, 0.51] -0.28 [-0.84, 0.28] 0.11 [-0.44, 0.67] 0.00 [-0.51, 0.51] -0.20 [-0.95, 0.55] 1.02 [-1.51, -0.01] 0.15 [-0.13, 0.42] -0.32 [-0.72, 0.07] 2.79 [-3.51, -2.07] 1.02 [-1.51, -0.52] % 5td. Mean Different t. VV. Random, 99 -0.22 [-0.73, 0 % -0.27 [-0.78, 0 % -0.31 [-0.24, 0 % -0.11 [-0.45, 0 % -0.11 [-0.57, 0] [-0.57, 0</td> <td>Year 1988 2005 2005 2005 2016 2016 2016 2016 2016 2016 2017 2017 2017 2017 2017 2018 2018 2018 2018 2018 2018 2018 2018 2019 2022 2023 2023 2024 2024 2025 2025 2025 2014 2016 2017 2017 2017 2018 2023 2022 2023 2022 2023 2022 2023 2024 2025 2055</td> <td>IV, Random, 95% CI</td>	VV. Random, 95% C1 1.86 [-2.56, -1.16] 0.95 [-1.48, -0.42] 1.39 [-1.96, -0.82] 1.39 [-1.96, -0.82] 1.39 [-1.96, -0.82] 0.30 [-0.86, 0.26] -0.08 [-0.84, 0.28] 0.10 [-0.51, 0.51] -0.28 [-0.84, 0.28] 0.11 [-0.44, 0.67] 0.00 [-0.51, 0.51] -0.20 [-0.95, 0.55] 1.02 [-1.51, -0.01] 0.15 [-0.13, 0.42] -0.32 [-0.72, 0.07] 2.79 [-3.51, -2.07] 1.02 [-1.51, -0.52] % 5td. Mean Different t. VV. Random, 99 -0.22 [-0.73, 0 % -0.27 [-0.78, 0 % -0.31 [-0.24, 0 % -0.11 [-0.45, 0 % -0.11 [-0.57, 0] [-0.57, 0	Year 1988 2005 2005 2005 2016 2016 2016 2016 2016 2016 2017 2017 2017 2017 2017 2018 2018 2018 2018 2018 2018 2018 2018 2019 2022 2023 2023 2024 2024 2025 2025 2025 2014 2016 2017 2017 2017 2018 2023 2022 2023 2022 2023 2022 2023 2024 2025 2055	IV, Random, 95% CI
Study or Subgroup Study or Subgroup Azemati 2005 (1) Azemati 2005 (2) Kasem 2014 Hamill 2015 Shah 2016 Gupta 2016 (1) Gupta 2016 (2) Chung 2017 (1) Chung 2017 (2) Cho 2018 Purdy 2018 (2) Kinjo 2019 Laguduvah 2022 Shi 2023 Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: Study or Subgroup Azemati 2005 (1) Azemati 2005 (2) Dingerman 2013 Gupta 2016 (1) Cupta 2016 (2) Hamill 2015 (kinjo 2019 Laguduvah 2022 Hamill 2015 (kinjo 2017 Purdy 2018 (1) Myazaki 2017 Purdy 2018 (1) Purdy 2018 (1)	Mean 1.6 2.7 2.7 2.75 2.75 2.75 2.75 2.75 0.92: C 0.92: C 2.75 1.33 2.32 3.342 2.75 0.92: C 2.75 1.68 2.75 0.92: C 2.75 1.68 2.22 2.54 3.42 2.22 2.54 3.74 3.44 2.22 2.54 3.74 3.44 3.44 3.44 3.44 3.44 3.44 3.44 3.44 3.44 3.44 3.44 3.44 3.44 3.44 3.44 3.44 3.44	SD 0.58 0.58 0.58 0.52 0.52 0.52 0.52 0.51 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 0.66 0.88 1.47 1.6 2.38 0.61 0.14 1.47 1.25 1.22 1.29 0.62 1.25 1.26 1.26 1.27 1.27 1.26 1.28 1.26 1.29 0.661 0.14 1.41 1.04 1.42 1.14 1.14 1.14 1.14 1.25 1.38 1.18 1.18 1.18 1.18 1.14 1.27	Total 22 223 30 30 30 23 63 30 23 63 30 25 25 25 25 25 25 25 25 25 25 25 25 30 16 12 30 543 007.28, 00.0001 0 707.28, 00.0001 0 707.28, 100 5 32 30 30 2 30 3 30 3 30 3 30 3 30 3 30 2 30 3 30 3 30 3 30 3 30 3 30 3 30 3 30 3 30	Mean 3.2 4 5 2.75 4.25 4.67 3.2 2.84 4.25 2.84 4.25 2.84 4 2 2.84 4 2 2.84 4 2 1.1 1.9 1.9 2.2 3.7 3.3 3.3 3.3 3.3 3.3 3.3 3.3	SD	Total V 24 244 24 24 24 30 31 30 22 67 30 25 25 25 25 25 25 25 25 25 25 30 12 12 101 50 30 539 1 50 0.00000	Veight 6.1% - 6.1% - 6.4% - 6.4% - 6.4% - 6.7% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% 6.4% - - 6.4% 6.4% - - 6.1% - - - 6.1% - - - 6.1% - - - 00.0% - 1): 1 ² 93 0 6.53 - - 5 6.33 - - 6.1% - - - 1 - - - - 5 6.33 - - - 5 6.33 - - - 5 6.33 - - -	VV. Random, 95% C1 1.86 [-2.56, -1.16] 0.95 [-1.48, -0.42] 1.39 [-1.96, -0.82] 1.39 [-1.96, -0.82] 6.57 [-7.88, -5.25] -0.30 [-0.86, 0.26] -0.38 [-0.64, 0.28] 0.11 [-0.44, 0.67] 0.00 [-0.51, 0.51] -0.28 [-0.84, 0.28] 0.15 [-0.13, 0.42] -0.32 [-0.72, 0.07] 2.79 [-3.51, -2.07] 4.02 [-1.51, -0.52] % Std. Mean Different V, Random, 95 -0.22 [-0.73, 0 0, 0.01 [-0.25, 0] % Std. Mean Different V, Random, 95 -0.22 [-0.73, 0] 0, 0.01 [-0.25, 0] 0, 0.01 [-0.57, 0] 0, 0.01 [-0.24, 0] 0,	Year 1988 2005 2005 2005 2014 2015 2016 2016 2016 2016 2016 2016 2017 2017 2018 2018 2012 2013 2012 2013 2012 2013 2012 2013 2012 2013 2014 2015 2014 2015 2015 2015 2015 2015 2015 2016 2016 2016 2016 2016 2016 2016 2016	IV, Random, 95% CI
Study or Subgroup Azemati 2005 (1) Azemati 2005 (2) Kasem 2014 Hamill 2015 Shah 2016 Gupta 2016 (1) Gupta 2016 (2) Chung 2017 (1) Chung 2017 (2) Chung 2017 (2) Chung 2017 (2) Chung 2017 (2) Chung 2017 (2) Chung 2018 (2) Kinjo 2019 Chung 2019 Chung 2019 Chung 2019 Chung 2017 (1) Chung 2017 (1) Chung 2017 (1) Chung 2017 (2) Dingerman 2013 Cupta 2016 (2) Hamill 2015 Kinjo 2019 Laguduvah 2022 Study or Subgroup Azemati 2005 (1) Chung 2017 (1) Chung 2017 (1) Chung 2017 (2) Dingerman 2013 Cupta 2016 (2) Hamill 2015 Kinjo 2019 Laguduvah 2022 Myazaki 2017 Purdy 2018 (1) Purdy 2018 (2) Purdy 2018 (2)	Mean 1.6 2.7 2.3 3.1 2.75 1.88 2.12 2.3 3.3 1.3 2.42 3 2.75 1.38 2.42 3 2.72 1.5 2.75 1.6 2.75 1.68 2.75 1.3 2.75 1.5 2.75 1.68 2.25 3.74 3.42 2.75 0.32 2.55 3.74 3.42 2.75 0.33 3.48 0.42	SD 0.58 0.52 0.52 0.52 0.52 0.52 0.52 0.51 1.25 1.25 1.25 0.66 0.88 1.47 0.61 0.14 hil ² = 2 0.61 0.14 hil ² = 2 0.62 1.25 0.61 0.14 hil ² = 2 0.61 0.14 1.25 0.201 1.41 1.02 1.41 1.03 1.44 2.44	Total 22 22 30 30 30 23 30 30 23 63 30 25 25 25 25 25 25 30 12 107 50 50 543 007.28, 0.0001 30 25 243 26 30 27 30 28 30 29 Total 20 255 25 25 26 30 29 700.0001 20 25 23 30 25 24 25 24 25 25 26 25 27 63 28 10 29 50 20 50 20 12 21 22	Mean 3.2 4 5 5 2.75 4.25 2.75 4.25 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.4 2.04 3.4 3.4 3.4 3.2 3.4 3.4 3.4 3.2 2.14 3.4 3.2 3.4 3.4 2.14 3.2 2.14 3.2 2.2 4.2 3.4 2.14 3.2 2.2 4.2 2.14 3.4 2.14 2.12 2.2 2.3 4.2 2.14 2.12 2.2 2.3 2.2 2.3 2.5 2.2 2.3 2.5 2.2 2.3 2.5 2.2 2.3 2.3 2.5 2.2 2.3 2.3 3.3 3.3 3.2 2.2 2.2	SD	Total % 24 24 24 31 30 22 67 30 22 25 25 25 25 25 25 30 12 12 101 50 539 1 58 33 8 33 8 38 9 2 26 6 6 2 26 6 6 2 10 5 1 5 3 2 2 6 6 6 2 10 5 1 5 1	Veight 6.1% - 6.1% - 6.4% - 6.4% - 6.4% - 6.7% - 4.7% - 6.4% 6.4% - 6.4% 6.4% 6.4% - 6.4% 6.4% 6.4% 6.4% - 6.7% - 0.0% - 0.00.0% - - - 0.1 1 ² - 93 d Weight - - 0.00.0% - - - 1.1 1 ² - 93 d Weight - - 0.00.0% - - - 1.1 1 ² - 93 d Weight - - 0.6 - - - 1.6 - - - 1.7 - - - 0.7 0 <td>VV, Random, 95% C1 1.86 [-2.56, -1.16] 0.95 [-1.48, -0.42] 1.39 [-1.96, -0.82] 1.39 [-1.96, -0.82] 1.39 [-1.96, -0.82] 0.30 [-0.86, 0.26] -0.08 [-0.84, 0.28] 0.11 [-0.44, 0.67] 0.00 [-0.51, 0.51] -0.28 [-0.84, 0.28] 0.15 [-0.13, 0.42] -0.35 [-1.59, -0.01] 0.15 [-0.13, 0.42] -0.35 [-1.51, -0.52] % 5td. Mean Different t V/, Random, 95 -0.27 [-0.73, 0 0.00 [-0.51, -0.52] % 5td. Mean Different t V/, Random, 95 0.02 [-0.73, 0 0.02 [-0.73, 0 0.03 [-0.75, 0 0.03 [-0.75, 0 0.03 [-0.75, 0 0.01 [-0.57, 0 0.01 [-0.45, 0 0.01 [-0.34, 0 0.01 [-0.34, 0 0.01 [-0.34, 0 0.01 [-0.34, 0 0.01 [-0.34, 0 0.01 [-0.34, 0 0.00 [-0.34, 0 0.078 [-1.44, -0.54] 0, 0.78 [-1.44, -0.54] 0, 0.78 [-1.44, -0.54] 0, 0.78 [-1.44, -0.54] 0, 0.78 [-0.04, 1] 0, 0.78 [-0.04,</td> <td>Year 1988 2005 2005 2005 2014 2016 2016 2016 2016 2016 2016 2016 2017 2017 2017 2017 2017 2017 2018 2018 2018 2019 2022 2023 2023 2023 2023 2023 2023 202</td> <td>IV, Random, 95% CI</td>	VV, Random, 95% C1 1.86 [-2.56, -1.16] 0.95 [-1.48, -0.42] 1.39 [-1.96, -0.82] 1.39 [-1.96, -0.82] 1.39 [-1.96, -0.82] 0.30 [-0.86, 0.26] -0.08 [-0.84, 0.28] 0.11 [-0.44, 0.67] 0.00 [-0.51, 0.51] -0.28 [-0.84, 0.28] 0.15 [-0.13, 0.42] -0.35 [-1.59, -0.01] 0.15 [-0.13, 0.42] -0.35 [-1.51, -0.52] % 5td. Mean Different t V/, Random, 95 -0.27 [-0.73, 0 0.00 [-0.51, -0.52] % 5td. Mean Different t V/, Random, 95 0.02 [-0.73, 0 0.02 [-0.73, 0 0.03 [-0.75, 0 0.03 [-0.75, 0 0.03 [-0.75, 0 0.01 [-0.57, 0 0.01 [-0.45, 0 0.01 [-0.34, 0 0.01 [-0.34, 0 0.01 [-0.34, 0 0.01 [-0.34, 0 0.01 [-0.34, 0 0.01 [-0.34, 0 0.00 [-0.34, 0 0.078 [-1.44, -0.54] 0, 0.78 [-1.44, -0.54] 0, 0.78 [-1.44, -0.54] 0, 0.78 [-1.44, -0.54] 0, 0.78 [-0.04, 1] 0, 0.78 [-0.04,	Year 1988 2005 2005 2005 2014 2016 2016 2016 2016 2016 2016 2016 2017 2017 2017 2017 2017 2017 2018 2018 2018 2019 2022 2023 2023 2023 2023 2023 2023 202	IV, Random, 95% CI
Study or Subgroup Azemati 2005 (1) Azemati 2005 (2) Azemati 2005 (2) Kasem 2014 Hamill 2015 Shah 2016 (2) Chung 2017 (1) Chung 2017 (2) Cho 2018 (2) Purdy 2018 (2) Kinjo 2019 Laguduvah 2022 Shi 2023 Total (95% C) Heterogeneity: Tau ² = Test for overall effect : Study or Subgroup Azemati 2005 (1) Azemati 2005 (1) Azemati 2005 (2) Chung 2017 (1) Chung 2017 (2) Dingerman 2013 Cupta 2016 (2) Hamill 2015 Kinjo 2019 Laguduvah 2022 Shi 2023 Shi 2023	Mean 1.6 2.7 2.7 2.75 2.72 3.3 3.3 4.42 2.75 3.44 3.75 3.74 3.75 3.75 3.75 3.75 3.75	SD 0.58 0.58 0.52 0.52 0.52 0.52 0.52 0.52 0.51 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.26 0.66 0.88 Mb ² = 2 0.92 1.21 0.22 0.32 0.32 0.32 0.32 0.32 0.32 0.32 0.32 0.32 0.32 0.32 0.33 0.34 0.35 0.36 0.37	Total 2 22 30 30 30 23 30 23 25 25 25 25 25 25 25 25 25 25	Mean 3.2 4 5 5 2.75 4.25 2.75 4.25 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4	SD SD 1.03 1.1.46 1.1.60 0.79 0.079 0.078 1.68 0.98 2.4 2.4 2.4 2.4 1.9 0.90 0.61 5 5 (P <	Total V 24 244 30 31 31 30 22 67 300 25 25 25 25 25 25 25 25 26 12 101 50 539 101 50 0.00000 66 33 88 30 50 2 9 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 3 2 3 2 2 2 3 2 4 3	Veight 6.1% - 6.1% - 6.4% - 6.4% - 6.4% - 6.7% - 6.7% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% 6.4% - 6.4% 6.4% 6.4% - 6.5% 6.7% - 6.1% - 0.0.5% - - - 0.1; 1 ² 93 - - 1.1 Weight - - 0 6.53 - - 5 6.33 - - 6.1% - - - 0 6.53 - - 5 6.33 - - 5 6.33 - - 1 7.72 - - 2 5.22	VV. Random, 95% C1 1.86 [-2.56, -1.16] 0.95 [-1.48, -0.42] 1.39 [-1.96, -0.82] 1.39 [-1.96, -0.82] 1.39 [-1.96, -0.82] 0.57 [-7.88, -5.25] -0.30 [-0.86, 0.26] -0.08 [-0.84, 0.28] 0.11 [-0.44, 0.67] 0.00 [-0.51, 0.51] -0.20 [-0.95, 0.55] 0.02 [-0.95, 0.55] 0.35 [-1.69, -0.07] 2.79 [-3.51, -2.07] 4.02 [-1.51, -0.52] % 5td. Mean Different IV. Random, 95 % -0.22 [-0.72, 0.07] 4.02 [-0.72, 0.07] 5.00 [-0.51, -0.52] % 5td. Mean Different IV. Random, 95 % -0.22 [-0.72, 0.07] 4.00 [-0.51, 0.52] % 0.013 [-0.87, 0 0.013 [-0.45, 0 0.013 [-0.45, 0 0.013 [-0.25, 0] 0.013 [-0.25, 0 0.013 [-0.25, 0] 0.013 [-	Year 1988 2005 2005 2005 2014 2015 2016 2016 2016 2016 2018 2018 2018 2018 2018 2018 2018 2018	IV, Random, 95% CI
Study or Subgroup Study or Subgroup Azemati 2005 (1) Azemati 2005 (2) Kasem 2014 Hamill 2015 Shah 2016 Gupta 2016 (1) Gupta 2016 (2) Chung 2017 (1) Chung 2017 (2) Cho 2018 Purdy 2018 (2) Kinjo 2019 Lagudwah 2022 Shi 2023 Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: Dingerman 2013 Cupta 2016 (2) Dingerman 2013 Cupta 2016 (2) Hamill 2015 Guipta 2016 (2) Hamill 2015 Kinjo 2019 Lagudwah 2022 Myazaki 2017 Myazaki 2017 Purdy 2018 (2) Shi 2023 Siripruekpong 20222	$\begin{array}{c} \textbf{Mean} \\ 1.6 \\ 2.7 \\ 2.7 \\ 2.7 \\ 2.7 \\ 2.7 \\ 2.7 \\ 2.7 \\ 2.7 \\ 2.7 \\ 2.7 \\ 2.7 \\ 2.7 \\ 2.7 \\ 2.7 \\ 2.7 \\ 3.2 \\ 4.0 \\ 2.7 \\ 2.7 \\ 3.2 \\ 4.0 \\ 2.7 \\ 3.7 \\ 3.2 \\ 4.0 \\ 3.7 \\ 3.7 \\ 3.4 \\ 3.4 \\ 3.7 \\ 3.4 \\ 3.4 \\ 3.7 \\ 3.4 \\ 3$	SD 0.58 0.52 0.52 0.52 0.52 0.52 0.52 0.51 1.25 1.25 1.25 1.25 1.25 0.66 0.88 1.47 1.6 2.38 0.61 0.14 1.6 1.25 1.22 0.94 1.04 1.04 1.04 1.04 1.14 1.25 0.33 1.34 1.34	Total 1 22 30 30 30 23 363 30 23 63 30 25 25 25 25 25 25 25 25 25 25 25 25 30 16 12 107 50 30 0.0001 07.28, 0.0001 0 707.28, 0.0001 0 707.28, 0.0001 0 707.28, 0.0001 0 707.28, 0.0001 0 707.28, 0.0001 0 707.28, 0.0001 0 707.28, 0.0001 0 707.28, 0.0001 0 303 12 25 12 25 12 25 12 25 12 25 12 25 13 30 14 16	Mean 3.2 4 5 2.75 4.25 2.84 4.67 3.2 2.84 4.25 2.84 4.2 2.84 4.25 4.2 2.84 4.2 2.84 4.2 2.84 4.2 2.84 4.25 2.14 3.25 2.14 3.25 2.14 3.25 2.14 3.25 2.14 3.25 2.14 3.25 2.14 3.25 2.14 3.25 2.14 3.25 2.14 3.25 2.14 3.25 2.14 3.25 2.14 3.25 2.14 3.25 2.14 3.25 2.14 3.25 2.14 3.25 2.14 3.25 2.14 3.25 2.37 3.3 3.3 3.3 3.3 3.3 3.3 3.3	SD	Total V 24 24 31 30 31 322 67 30 22 25 25 25 25 25 25 25 25 26 101 50 0.00000 539 1 50 30 66 31 88 39 66 2 9 2 20 2 21 2 22 2 23 2 24 2 25 2 26 10 88 11 5 1.1 5 3 9 3	Veight 6.1% - 6.1% - 6.4% - 6.4% - 6.4% - 6.7% - 6.7% - 6.4% 6.4% 6.4% 6.4% 6.4% 6.4% 6.4% 6.4% 6.4% 6.4% 6.4% 6.4% 6.4% 6.4% 6.4% 6.4% 6.1% - 6.1% - 00.0% - 1): 1 ² 93 0 6.55 6.33 - 5 6.33 - 6.55 0 6.55 6.33 - 5 6.33 - - 6.1% - 7.21 - 1 7.52 0 7.02 - 2 5.27 2.5.21 4.90 - 0 5.12 4.92 - -	VV. Random, 95% CI 1.36 [-2.56, -1.16] 0.95 [-1.48, -0.42] 1.39 [-1.96, -0.82] 1.39 [-1.96, -0.82] 1.31 [-1.74, -0.48] 1.48 [-0.64, -0.82] 0.57 [-7.88, -5.25] -0.30 [-0.86, 0.26] -0.38 [-0.64, 0.42] 0.11 [-0.44, 0.67] 0.00 [-0.51, 0.42] -0.22 [-0.72, 0.07] 2.79 [-3.51, -2.07] -1.02 [-1.51, -0.52] % 0.00 [-0.51, 0 % 0.00 [-0.51, 0 % 0.15 [-0.13, 0.42] -0.32 [-0.72, 0.07] 2.79 [-3.51, -2.07] 1.02 [-1.51, -0.52] % 0.00 [-0.51, 0 % -0.22 [-0.73, 0 % 0.01 [-0.57, 0 % 0.13 [-0.45, 0 % 0.10 [-0.24, 0 % 0.11 [-0.45, 0 % 0.10 [-0.24, 0 % 0.10 [-0.44, 0 % 0.024 [-1.80, -0 % 0.034 [-0.44, 1.8, -2 % <	Year 1988 2005 2005 2014 2015 2016 2016 2016 2016 2016 2016 2017 2018 2012 2013 2012 2013 2012 2013 2012 2013 2012 2013 2012 2013 2012 2014 2015 2015 2015 2015 2015 2015 2015 2015	IV, Random, 95% CI
Study or Subgroup Starmati 2005 (1) Azemati 2005 (1) Azemati 2005 (1) Azemati 2005 (2) Casem 2014 Hamill 2015 Shah 2016 Cupta 2016 (2) Chung 2017 (1) Chung 2017 (2) Chung 2017 (2) Chung 2017 (2) Murdy 2018 (2) Study or Subgroup Azemati 2005 (2) Azemati 2005 (2) Azemati 2005 (2) Chung 2017 (1) Chung 2017 (1) Chung 2017 (1) Chung 2017 (2) Dingerman 2013 Cupta 2016 (2) Hamill 2015 Cinjo 2018 Chung 2017 (1) Chung 2017 (2) Dingerman 2013 Cupta 2016 (2) Hamill 2015 Cinjo 2019 Cupta 2016 (2) Hyazaki 2017 Yurdy 2018 (1) Yurdy 2018 (2) Shirpruekpong 2022 Total (95% CI)	Mean 1.6 2.7 2.7 2.3 3.53 1 2.75 3.42 2.55 2.55 2.55 2.55 3.42 2.55 3.42 2.55 3.42 2.55 3.42 2.55 3.42 2.55 3.42 2.55 3.42 3.42 2.55 3.44 2.25 3.44 2.25 3.44 2.25 3.44 3.42 2.55 3.44 3.42 2.55 3.44 3.42 2.55 3.44 3.42 3.44 3.45 3.45 3.44 3.45 3	SD 0.58 1.22 1.22 0.5 1.22 0.5 1.22 0.5 1.25 0.61 1.25 0.66 0.88 1.25 0.61 1.47 1.6 SC 0.61 1.27 1.23 0.61 SC 1.27 1.28 0.61 SC 1.27 1.28 0.61 SC 1.28 0.61 1.22 1.22 1.22 1.22 1.20 1.47 1.34 1.34 1.34 1.34 1.34 1.34	Total 22 22 30 30 30 23 30 30 23 63 30 25 25 25 25 25 25 26 30 107 50 50 543 007.28, 8 30 25 24 25 25 26 30 50 543 25 26 26 12 27 63 28 30 30 30 30 30 25 26 26 25 27 63 28 30 30 32 30 32 30 32 30 32 30 32 30 32 31 32 32 </td <td>Mean 3.2 4 5 5 2.75 4.25 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.4 2.04 2.2 2.3 2.3 2.2 2.3 2.2 2.3 2.2 2.3 2.2 2.3 2.2 2.3 2.2 2.3 2.2 2.3 2.2 2.3 2.2 2.3 2.2 2.3 2.2 2.3 2.2 2.2</td> <td>SD 1.03 1.46 1.96 0.79 0.78 1.68 0.90 0.45 0.92 0.93 2.4 1.9 0.90 0.61 5 (P <</td> 0.91 5 (P <	Mean 3.2 4 5 5 2.75 4.25 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.2 2.84 4.67 3.4 2.04 2.2 2.3 2.3 2.2 2.3 2.2 2.3 2.2 2.3 2.2 2.3 2.2 2.3 2.2 2.3 2.2 2.3 2.2 2.3 2.2 2.3 2.2 2.3 2.2 2.3 2.2 2.2	SD 1.03 1.46 1.96 0.79 0.78 1.68 0.90 0.45 0.92 0.93 2.4 1.9 0.90 0.61 5 (P <	Total V 24 24 24 31 30 31 30 22 67 30 25 25 25 25 25 25 30 12 101 50 530 12 101 50 530 6 2 6 6 2 2 2 2 2 2 2 2 2 2 2 2 2 3 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 38 11 5	Veight 6.1% - 6.1% - 6.4% - 6.4% - 6.4% - 6.3% - 6.7% - 4.7% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% - 6.4% 6.4% - - 6.5% 6.0% - - 6.7% - - - 00.0% - - - 1): 1 ² 93 - - 4! Weight - - 00.0% - - - 1): 1 ² 93 - - 4! Weight - - 0 6.5% - - 5 6.3% - - 6 - - - 0 7.0% - - 2 5.2%	IV, Random, 95% CI 1.86 [-2.56, -1.16] 0.95 [-1.48, -0.42] 1.39 [-1.96, -0.82] 1.39 [-1.96, -0.82] 0.30 [-0.86, 0.26] -0.30 [-0.86, 0.26] -0.30 [-0.86, 0.26] -0.30 [-0.86, 0.26] -0.30 [-0.86, 0.26] -0.30 [-0.86, 0.26] -0.30 [-0.51, 0.51] -0.30 [-0.53, 0.51] -0.32 [-0.72, 0.07] 0.35 [-1.69, -0.01] 0.35 [-1.69, -0.01] 0.35 [-1.51, -0.52] % -0.22 [-0.73, 0.42] *0.25 [-0.73, 0.42] *0.25 [-0.73, 0.42] *0.35 [-1.51, -0.52] % -0.32 [-0.73, 0.42] *0.32 [-0.73, 0.42] *0.32 [-0.73, 0.42] *0.32 [-0.73, 0.42] *0.32 [-0.73, 0.42] *0.32 [-0.73, 0.42] *0.32 [-0.73, 0.42] *0.32 [-0.73, 0.42] *0.32 [-0.73, 0.42] *0.32 [-0.73, 0.42] *0.32 [-0.73, 0.42] *0.32 [-0.73, 0.42] *0.32 [-0.74, 0.43] *0.32 [-0.75, 0.43]	Year 1988 2005 2005 2005 2014 2016 2016 2016 2016 2016 2016 2016 2016	IV, Random, 95% CI

Figure 3: Forest plot demonstrating overall RSB performance compared to control, (a) 0-2 h, (b) 10-12 h, and (c) 12-24 h postoperatively. The random-effects model was used to review studies with continuous variables. Standardised mean ratios are presented with 95% confidence intervals. RSB = rectus sheath block, CI = Confidence Interval, SD = Standard Deviation. *Numbers in parentheses delineate separate groups when more than one cohort was under investigation in a given trial

and Zhen *et al.* in 2022,^[9] but the methodologies of these findings were limited to adult laparoscopic surgery and paediatric umbilical hernia repairs, respectively.

Increasing the breadth of knowledge upon which to draw through our inclusion of all relevant surgical procedures in which the RSB may now be utilised, we have therefore here expanded on previous findings in the literature by conducting the most comprehensive RSB review to date and believe that the RSB should continue to be considered an effective treatment measure for not just laparoscopic interventions, but all relevant abdominal surgical procedures.

Abdominal peripheral nerve blocks are currently seen as adequate and reliable methods for the treatment of adult and paediatric postoperative pain following both open and laparoscopic abdominal procedures.^[44,45] Despite epidural or intrathecal methods being the current gold standard, certain situations may arise where an epidural approach is either not possible or unnecessary.^[3] With its cost-effectiveness, ease of use and rising popularity due to relatively low complication rates since the inception of ultrasound guidance, the RSB should be considered an ideal choice when such situations present themselves.^[46] Here, we confirmed previous results published on the RSB's efficacy in abdominal procedures while bridging the gap in the literature between open and laparoscopic RSB usage, highlighting its more comprehensive applications and building on previous findings in more specialised surgery domains. We recommend that the RSB be used in instances where appropriate for abdominal procedures in which no other analgesic intervention has been considered, particularly for minor operations with high postoperative pain management needs and a low average time to discharge.

Despite the robust nature of our review, several limitations existed within our study parameters. First, several issues related to reporting and obtaining data from all the trials included. Some studies did not report pain scores during our allotted time intervals, others did not collect discernable data during those intervals, and others used non-opioid analgesics for postoperative pain or did not report analgesic use at all. This strict inclusion criteria limited the author's ability to report on all studies. Still, the inclusion criteria were designed to reduce heterogeneity and bias by focussing on a set level of objective metrics where possible. Funnel plots were additionally generated for the primary and secondary outcomes [SDC Figures 4-7]. The graphical representation presents a visual of the extent of publication bias. A relatively symmetrical shape in all figures representing the primary outcomes suggests little publication bias in continuous results. Yet, it is more significant in secondary analysis outcomes due to less symmetry. In circumstances where multiple groups were included in one study and could lead to a potential unit-of-analysis issue through the influence of the control group data weighting, care was taken to maintain the independence of each comparison where possible by treating each intervention group separately.

Unfortunately, a high degree of heterogeneity between the studies analysed was still observed. This high degree of heterogeneity likely reflects the many differing types of surgical procedures employed, type of local anaesthetic utilised, timing of the block, postoperative analgesia chosen and differences in control regimens. These effects were also likely exacerbated by the differences in participant comorbidities, age and some level of self-reporting bias. Our search strategy was designed to capture a comprehensive range of studies in RSB, including those that employ varied surgical techniques. This inclusive approach aimed to provide a meta-analysis reflecting the current evidence state across clinically relevant applications. We implemented this strategy to give a detailed insight into current practice and future research trajectories. We attempted to further decrease heterogeneity by analysing subgroup outcomes based on the type of surgical intervention. However, levels were still seen as high in the laparoscopic subgroup - limiting the power of meta-analytic results. However, this degree of heterogeneity was expected and is consistent with other previous peripheral nerve block review findings reported in the literature.^[7-9]

During this review, we identified some areas for future research. A clear focus should be put into the RSB's efficacy in comparison to other newer and widely utilised abdominal nerve blocks such as the quadratus lumborum block, erector spinae plane block, ilioinguinal-iliohypogastric block, pericapsular nerve group block and transversalis fascia plane block. Researchers should also consider implementing more in-depth timing of pain scores to determine better how long the efficacy of a nerve block truly is, rather than relying on large, open-ended time periods as is currently commonplace. Additionally, it should become standard practice to be more transparent in reporting such findings. These small changes would increase the ability of researchers to aggregate larger sums of data on nerve block efficacy so that patient populations may benefit from an increased number of included studies in future reviews. Finally, the comparative efficacy of ultrasound, laparoscopic, blind loss-of-resistance and surgically guided techniques in RSB implementation need to be explored once enough data on the subject is available.

CONCLUSIONS

We conclude that the rectus sheath block may be a safe and effective intervention for reducing surgical pain in abdominal procedures, with a heightened efficacy noted in the initial 2 h postoperatively. Implementation of rectus sheath block was additionally associated with decreased opioid consumption, in intravenous morphine equivalency, for up to 24 h following surgical intervention. Moderate-low evidence and substantial statistical heterogeneity were observed in the 20 trials included in this review. Further high-quality research is required to reach an optimal benefit assessment of rectus sheath block.

Financial support and sponsorship Nil.

Conflicts of interest

RH and TMH are Shareholders of Divocco AI, Montreal, Canada.

ORCID

Sean D. Jeffries: https://orcid.org/0000-0001-5079-5380

Robert Harutyunyan: https://orcid.org/0000-0003-0982-6741

Joshua Morse: https://orcid.org/0009-0007-4747-2418 Thomas M. Hemmerling: https://orcid.org/0000-0002-1447-0703

REFERENCES

- 1. Onwochei DN, Børglum J, Pawa A. Abdominal wall blocks for intra-abdominal surgery. BJA Educ 2018;18:317-22.
- 2. Uppal V, Sancheti S, Kalagara H. Transversus Abdominis Plane (tap) and rectus sheath blocks: A technical description and evidence review. Curr Anesthesiol Rep 2019;9:479-87.
- Fernandes HDS, Azevedo AS, Ferreira TC, Santos SA, Rocha-Filho JA, Vieira JE. Ultrasound-guided peripheral abdominal wall blocks. Clinics 2021;76:e2170. doi: 10.6061/ clinics/2021/e2170.
- Chin KJ, McDonnell JG, Carvalho B, Sharkey A, Pawa A, Gadsden J. Essentials of our current understanding. Reg Anesth Pain Med 2017;42:133-83.
- Miyazaki D, Shichinohe T, Ebihara Y, Kurashima Y, Murakami S, Noji T, *et al.* Laparoscopic-assisted rectus sheath block as a novel technique is effective and safe: A randomized controlled trial. Surg Laparosc Endosc Percutan Tech 2017;27:19-23.
- Abdildin Y, Tapinova K, Salamat A, Shaimakhanov R, Aitbayev A, Viderman D. Rectus sheath block in abdominal surgery: A systematic review with meta-analysis. Rom J Anaesth Int Care 2023;30:43-50.
- Hamid HKS, Ahmed AY, Alhamo MA, Davis GN. Efficacy and safety profile of rectus sheath block in adult laparoscopic surgery: A meta-analysis. J Surg Res 2021;261:10-7.
- 8. Hamill JK, Rahiri J-L, Liley A, Hill AG. Rectus sheath and transversus abdominis plane blocks in children: A systematic

review and meta-analysis of Randomized Trials. Paediatr Anaesth 2016;26:363-71.

- Zhen L-H, Wang H-B, Zhou Y. Comparison of rectus sheath block and local anesthetic for analgesia in pediatric umbilical hernia repair: A systematic review and meta-analysis. Medicine (Baltimore) 2022;101:e30391. doi: 10.1097/md. 000000000030391.
- Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. J Clin Epidemiol 2009;62:e1-34.
- 11. Chapman AL, Morgan LC, Gartlehner G. Semi-automating the manual literature search for systematic reviews increases efficiency. Health Info Libr J 2010;27:22-7.
- Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for systematic reviews. Syst Rev 2016;5:210.
- Brozek JL, Canelo-Aybar C, Akl EA, Bowen JM, Bucher J, Chiu WA, et al. GRADE Guidelines 30: The GRADE approach to assessing the certainty of modeled evidence-An overview in the context of health decision-making. J Clin Epidemiol 2021;129:138-50.
- 14. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, *et al.* RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ 2019;366:14898.
- López-López JA, Page MJ, Lipsey MW, Higgins JPT. Dealing with effect size multiplicity in systematic reviews and metaanalyses. Res Syn Meth 2018;9:336-51. doi: 10.1002/jrsm. 1310.
- Chou R, Fanciullo GJ, Fine PG, Adler JA, Ballantyne JC, Davies P, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009;10:113-30.
- Pereira J, Lawlor P, Vigano A, Dorgan M, Bruera E. Equianalgesic dose ratios for opioids. A critical review and proposals for long-term dosing. J Pain Symptom Manage 2001;22:672-87.
- Luo D, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. Stat Methods Med Res 2018;27:1785–805.
- Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol 2014;14:135.
- Rohatgi A. 2010. Available from: https://automeris.io/ WebPlotDigitizer/.
- Chakraborty A, Khemka R, Datta T. Ultrasound-guided truncal blocks: A new frontier in regional anaesthesia. Indian J Anaesth 2016;60:703-11.
- 22. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
- Melsen W, Bootsma M, Rovers M, Bonten JM. The effects of clinical and statistical heterogeneity on the predictive values of results from meta-analyses. Clin Microbiol Infect 2014;20:123-9.
- 24. Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. Available from: www. handbook.cochrane.org. [Last accessed on 2022 Nov 12].
- 25. Smith BE, Suchak M, Siggins D, Challands J. Rectus sheath block for diagnostic laparoscopy. Anaesthesia 1988;43:e947-8.
- Azemati S, Khosravi MB. An assessment of the value of rectus sheath block for postlaparoscopic pain in gynecologic surgery. J Minim Invasive Gynecol 2005;12:12–5.
- Isaac LA, McEwen J, Hayes JA, Crawford MW. A pilot study of the rectus sheath block for pain control after umbilical hernia repair. Paediatr Anaesth 2006;16:406–9.
- 28. Gurnaney HG, Maxwell LG, Kraemer FW, Goebel T, Nance ML, Ganesh A. Prospective randomized observer-blinded study comparing the analgesic efficacy of ultrasound-guided rectus sheath block and local anaesthetic infiltration for umbilical hernia repair. Br J Anaesth 2011;107:790–5.

- 29. Dingeman RS, Barus LM, Chung HK, Clendenin DJ, Lee CS, Tracy S, *et al.* Ultrasonography-guided bilateral rectus sheath block vs local anesthetic infiltration after pediatric umbilical hernia repair: A prospective randomized clinical trial. JAMA Surg 2013;148:707–13.
- 30. Kasem AA, AbdelKader AA. Ultrasound-guided rectus sheath block versus local infiltration in management of pain after single-incision laparoscopic cholecystectomy. Ain-Shams J Anesth 2015;8:100e106. doi: 10.4103/1687-7934.153950.
- Hamill JK, Liley A, Hill AG. Rectus sheath block for laparoscopic appendicectomy: A randomized clinical trial. ANZ J Surg 2015;85:951–6.
- 32. Gupta M, Naithani U, Singariya G, Gupta S. Comparison of 0.25% ropivacaine for intraperitoneal instillation v/s rectus sheath block for postoperative pain relief following laparoscopic cholecystectomy: A prospective study. J Clin Diagn Res 2016;10:UC10–5.
- Shah VA, Bajaj M. Ultrasound guided rectus sheath block in management of pain in laparoscopic tubal ligation. Anaesth Intensive Care 2019;20:e436-8.
- 34. Chung W, Yoon Y, Kim JW, Kwon SI, Yang JB, Lee KH, et al. Comparing two different techniques of rectus sheath block after single port laparoscopic surgery in benign adnexal mass patients: Surgical versus ultrasonography guidance-A randomized, single-blind, case-controlled study. Eur J Obstet Gynecol Reprod Biol 2017;217:29-33.
- 35. Uchinami Y, Sakuraya F, Tanaka N, Hoshino K, Mikami E, Ishikawa T, *et al.* Comparison of the analgesic efficacy of ultrasound-guided rectus sheath block and local anesthetic infiltration for laparoscopic percutaneous extraperitoneal closure in children. Paediatr Anaesth 2017;27:516–23.
- 36. Cho S, Kim YJ, Jeong K, Hoshino K, Mikami E, Ishikawa T, et al. Ultrasound-guided bilateral rectus sheath block reduces early postoperative pain after laparoscopic gynecologic surgery: A randomized study. J Anesth 2018;32:189–97.
- 37. Purdy M, Kinnunen M, Kokki M, Anttila M, Eskelinen M, Hautajärvi H, *et al.* A prospective, randomized, open label, controlled study investigating the efficiency and safety of 3 different methods of rectus sheath block analgesia following

midline laparotomy. Medicine 2018;97:e9968. doi: 10.1097/MD.00000000009968.

- Kinjo Y, Kurita T, Fujino Y, Kawasaki K, Yoshino K, Hachisuga T. Evaluation of laparoscopic-guided rectus sheath block in gynecologic laparoscopy: A prospective, double-blind randomized trial. Int J Surg 2019;62:47–53.
- Suragul W, Tantawanit A, Rungsakulkij N, Muangkaew P, Tangtawee P, Mingphrudhi S, et al. Effect of local anaesthetic infiltration on postoperative pain after laparoscopic cholecystectomy: Randomized clinical trial. BJS Open 2022;6:zrac066. doi: 10.1093/bjsopen/zrac066.
- 40. Siripruekpong S, Aphinyankul J, Chanchayanon T, Oofuvong M, Pakpirom J, Choksuchat C, *et al.* Minimal effective dose of ultrasound-guided rectus sheath block to reduce oral analgesic requirement after ambulatory laparoscopic tubal resection: A randomized controlled superiority trial. Trials 2022;23:228.
- 41. Laguduvah A, Swaminathan S, Satya Prakash MVS, A M. Comparison of postoperative analgesic efficacy of ultrasound-guided bilateral rectus sheath block with that of local anaesthetic infiltration in patients undergoing emergency midline laparotomy surgeries: A Randomised controlled trial. Cureus 2022;14:e31033. doi: 10.7759/cureus.31033.
- 42. Shi DW, Zhou XD, Wang FJ, Wang J, Liu Y, Niu Y, *et al.* Opioid-sparing effect of multi-point incision-based rectus sheath block in laparoscopic-assisted radical gastrectomy: A randomized clinical trial. J Clin Med 2023;12:1414.
- 43. Yörükoğlu HU, Şahin T, Öge Kula A. Transversus abdominis plane block versus rectus sheath block for postoperative pain after caesarean delivery: A randomised controlled trial. Turk J Anaesthesiol Reanim 2023;51:43-8.
- 44. Børglum J, Gögenür I, Bendtsen TF. Abdominal wall blocks in adults. Curr Opin Anaesthesiol 2016;29:638-43.
- 45. Willschke H, Kettner S. Pediatric regional anesthesia: Abdominal wall blocks. Paediatr Anaesth 2012;22:88–92.
- Gray AT. Rectus sheath block. In: Atlas of Ultrasound-Guided Regional Anesthesia. Vol 1. 3rd ed. San Francisco, CA: Elsevier; 2018. p. 249-58.

SUPPLEMENTAL DATA CONTENT (SDC)



Figure 1: Forest plot demonstrating open surgery subgroup analysis of RSB performance compared to control 0-2 h postoperatively



Figure 2: Forest plot demonstrating laparoscopic surgery subgroup analysis of RSB performance compared to control 0-2 h postoperatively. SD = standard deviation, CI = confidence interval

		RSB		N	o RSB			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Cho 2018	9	3.4	30	9.7	4.4	30	9.4%	-0.18 [-0.68, 0.33]	-+
Chung 2017 (1)	10.7	6.2	25	16.4	11.1	25	9.3%	-0.62 [-1.19, -0.06]	
Chung 2017 (2)	10.8	7.9	25	16.4	11.1	25	9.3%	-0.57 [-1.14, -0.01]	
Gupta 2016 (1)	7.2	3.5	25	19.4	2.6	25	8.5%	-3.90 [-4.86, -2.93]	
Gupta 2016 (2)	7.2	3.5	25	11.4	3	25	9.2%	-1.27 [-1.88, -0.66]	
Kasem 2014	10	2.5	23	17	4.5	22	9.0%	-1.90 [-2.62, -1.19]	
Laguduvah 2022	12.81	0.96	50	18.75	0.83	50	8.4%	-6.57 [-7.58, -5.56]	•
Purdy 2018 (1)	1.62	0.6	16	2.2	1	12	8.9%	-0.71 [-1.48, 0.07]	
Shi 2023	8.5	2.1	30	11	2	30	9.3%	-1.20 [-1.76, -0.65]	
Siripruekpong 2022	1.2	4	32	1.65	4.86	34	9.4%	-0.10 [-0.58, 0.38]	-
Yorukoglu 2023	15.07	4.47	30	17.95	4.22	30	9.3%	-0.65 [-1.17, -0.13]	
Total (95% CI)			311			308	100.0%	-1.55 [-2.35, -0.74]	•
Heterogeneity: Tau ² =	= 1.75: 0	Chi ² =	188.41	. df = 1	0 (P <	0.000	()(1): $ ^2 = 9$	5%	
Test for overall effect	:: Z = 3.7	75 (P =	= 0.000	2)					-4 -2 0 2 4 Favours [RSB] Favours [No RSB]

Figure 3: Forest plot demonstrating overall RSB performance compared to control in 24-h IV morphine equivalency (mg). SD = standard deviation, CI = confidence interval



Figure 4: Funnel plot of primary outcome: Pain assessment at 0-2 h postoperatively



Figure 5: Funnel plot of primary outcome: Pain assessment at 10-12 h postoperatively



Figure 6: Funnel plot of primary outcome: Pain assessment at 12-24 h postoperatively



Figure 7: Funnel plot of secondary outcome: Morphine equivalency at 24 h $\,$

	Table 1: Example of detailed <1996 to 2023	search strategy Embase Week 36>
#	Query	Results from 1 Sept 2023
1	Rectus sheath block.mp.	374
2	abdominal field block.mp.	15
3	1 or 2	386
4	anaesthesia/	83,645
5	analgesia/	135,534
6	block.mp.	336,306
7	inject.mp.	13,570
8	infusion/	63,528
9	4 or 5 or 6 or 7 or 8	604,074
10	randomised controlled trial/	748,474
11	controlled.mp.	10,161,878
12	clinical trial/	940,132
13	randomised.mp.	1,364,560
14	10 or 11 or 12 or 13	10,728,293
15	3 and 9 and 14	201